# Appendix P Evaluation of Physiologically Based Pharmacokinetic Models of Ethylbenzene for Application in VCCEP Assessment

### **EXECUTIVE SUMMARY**

Due to the substantial impact and diversity of the physiologically based pharmacokinetic (PBPK) model applications in the ethylbenzene VCCEP risk assessment, a thorough review and evaluation of the PBPK models for ethylbenzene is provided to delineate their strengths, limitations and range of applicability. For simulations of kinetics in Sprague-Dawley rats, the model of Krishnan and colleagues is preferred over the Dennison model because it more accurately predicts blood levels of ethylbenzene. There are, however, limitations to the circumstances under which the Krishnan rat model can be applied reliably. The Krishnan model can be used with high confidence for adult SD rats at concentrations at or below 200 ppm, moderate-to-high confidence for adult SD rats between 200 and 650 ppm. The oral model can be used with confidence for doses up to 180 mg/kg. The Dennison model produced a superior fit to data sets collected using F344 rats, as compared to the Krishnan model performance. The Dennison model can be used with moderate confidence for F344 rats at low to intermediate concentrations, but cannot be confidently used for high concentrations. However, none of the key studies in the VCCEP risk assessment require simulation of toxicokinetics in F344 rats. Given that there is some evidence for strain differences based on the modeling of F344 and Sprague-Dawley rats, the question of which model to use for other strains of rats needs to be considered. Of greatest relevance to the current effort is consideration of Wistar rats, which were used in the key oral noncancer study (Mellert et al., 2004). Based on the studies of urinary excretion of metabolites and the total amount of metabolism by Wistar rats, the models were equally successful. The Krishnan model, however, performed significantly better in predicting the post exposure exhalation of ethylbenzene. Based on this evaluation, we recommend the use of the Krishnan model for Wistar rats. The mouse model (Nong et al., 2006) adequately describes the blood and tissue kinetics of ethylbenzene in mice exposed to 75 to 750 ppm ethylbenzene in single or repeated exposures. Nong *et al.* (2006) have noted uncertainty with regard to the precise location of the extensive extrahepatic metabolism that is evident for ethylbenzene-exposed mice. This model can be confidently used to estimate blood and tissue ethylbenzene concentrations, and liver and whole-body metabolism for acute and repeated exposures up to 750 ppm ethylbenzene. The development of alternative descriptions of extrahepatic metabolism allowed for conservative estimation of lung metabolism for acute and repeated exposures up to 750 ppm. The human model assumes a body weightnormalized metabolic rate equivalent to that determined for Sprague-Dawley rats (Tardif et al., 1997). Although this assumption was initially validated only against blood and breath data from a 33-ppm exposure, the model was found to predict data from low level occupational exposures and higher concentration volunteer exposures with acceptable accuracy. Based on the ability of the model to reproduce blood concentrations from the low-level, occupational exposures, the PBPK model can be used with high confidence for humans exposed to ethylbenzene at all exposure levels expected to be relevant to the VCCEP analyses.

### INTRODUCTION

Physiologically-based pharmacokinetic (PBPK) models are useful tools that may be applied in a variety of risk assessment contexts (U.S. EPA, 2006). For this VCCEP assessment, PBPK models have been used to estimate the levels of ethylbenzene in human breast milk consumed by infants (Section 6.1.3; Appendix N); for calculation of inputs to rodent dose-response evaluations, interspecies extrapolation, and route-to-route extrapolation in the derivation of human toxicity reference values (Section 8); and as an aid in interpreting ethylbenzene biomonitoring data (Appendix R). Due to the substantial impact and diversity of the PBPK model applications in the ethylbenzene VCCEP risk assessment, a thorough review and evaluation of the PBPK models for ethylbenzene is provided to delineate their strengths, limitations and range of applicability.

Two PBPK models for ethylbenzene disposition in rats were identified from the literature. The first was developed at the University of Montreal by Kannan Krishnan and co-workers (Krishnan model; Tardif et al., 1997; Haddad et al., 1999, 2000; Faber et al., 2006 and unpublished data). The second was developed at Colorado State University by Jim Dennison (Dennison model; Dennison et al., 2003). The models have the same structure (i.e., same compartments) (Figure P-1) and used the same blood:air and tissue:air partition coefficient values; physiological parameters (blood flows, ventilation rate, tissue volumes) were slightly different between the models (Table P-1). Both models were developed to describe kinetics of a single exposure to inhaled ethylbenzene as a single chemical or in a mixture with other hydrocarbons, but the models were developed using different types of data. The Krishnan model was initially developed using concentrations of ethylbenzene in blood collected after inhalation exposure of male Sprague-Dawley rats (Tardif et al., 1996). Kinetic parameters for this model were refined based on additional studies of interactions among chemicals in mixtures (Haddad et al., 1999, 2000). The Krishnan model was extended to describe blood ethylbenzene concentrations measured after single and repeated gavage dosing (Faber et al., 2006 and Krishnan, 2002, unpublished data). For this VCCEP assessment, the Krishnan rat model was modified slightly, with the addition of a second, low-affinity metabolism pathway in the liver, to improve simulations of model simulations of blood concentration at higher (>200 ppm) exposure concentrations (described in greater detail below). The Dennison model was developed using closed-chamber gas uptake data for male Fischer 344 (F344) rats (Dennison et al., 2003). The models have similar values for the maximal rate of metabolism, but the Michaelis constants (KMs) are very different (Table P-1).

In the course of the ethylbenzene VCCEP assessment, the rat PBPK model was applied to scenarios other than those for which the models were developed. For example it was used to predict kinetics at other exposure concentrations, multi-day exposure, and to estimate dose metrics for which the model had not previously been validated such as metabolite production. For both rat models, we replicated the simulations for ethylbenzene-only exposure that were used to develop the models. We further tested the models against additional published data from the literature and unpublished data.



Figure P-1. PBPK model structure for ethylbenzene

Table P-1.	Parameter	values for	PBPK	modeling	of eth	ylbenzene	in rats,	mice,	and humans
------------	-----------	------------	------	----------	--------	-----------	----------	-------	------------

Parameter (units)	MICE (Nong		RAT	ГS	HUMANS	
	et al., 2006)	Krishnan Model <sup>a</sup>	Dennison Model <sup>b</sup>	PND 22 Pup <sup>c</sup>	At Rest <sup>d</sup>	50 W <sup>e</sup>
Body weight (kg)	0.025	0.25	0.22	0.0428-0.0439		70
Pulmonary ventilation (L/hr/kg <sup>0.75</sup> )	23	15	12	16.9	18	40
Cardiac output (L/hr/kg <sup>0.75</sup> )	15.6	15	15	13.2	18	26
Fractional tissue volume of fat	0.10	0.07	0.08	0.087		0.19
Fractional tissue volume of liver	0.055	0.04	0.037	0.036	(	0.026
Fractional tissue volume of richly perfused tissues (RPT)	0.05	0.05	0.054	0.23		0.05
Fractional tissue volume of slowly perfused tissues (SPT)	0.70	0.75	0.709	0.55		0.62
Fractional tissue volume of lung	0.0073	Not	Not	Not applicable	Not a	pplicable
tissues		applicable	applicable			
Fractional blood flows to fat	0.09	0.09	0.07	0.051	0.05	0.07
Fractional blood flows to liver	0.25	0.25	0.183	0.217	0.26	0.13
Fractional blood flows to RPT	0.51	0.51	0.51	0.332	0.44	0.3
Fractional blood flows to SPT	0.15	0.15	0.237	0.4	0.25	0.5
Partition coefficient (blood:air)	52.8 (m), 65.4 (f)		42.	7		28.0
Partition coefficient (lung:air)	63.84	Not applicable		licable	Not a	pplicable
Partition coefficient (liver:air)	72.9		83.	8		83.8
Partition coefficient (fat:air)	1417		155	i6		1556
Partition coefficient (RPT:air)	60.37 <sup>f</sup>		60.	3		60.3

Parameter (units)	MICE (Nong		RAT	ГS	HU	MANS
	et al., 2006)	Krishnan Model <sup>a</sup>	Dennison Model <sup>b</sup>	PND 22 Pup <sup>c</sup>	At Rest <sup>d</sup>	50 W <sup>e</sup>
Partition coefficient (SPT:air)	45.57		26	j		26
Michaelis constant, liver metabolism (mg/L), high affinity pathway <sup>g</sup>	1.04	1.04	0.1	Dennison and Krishnan values tested		1.04
Maximum metabolism rate in the liver (mg/hr/kg <sup>0.74</sup> )	6.39 (single) 19.4 (repeat)	6.39/5.59 <sup>g</sup>	7.6			6.39
Michaelis constant, liver metabolism (mg/L), low affinity pathway <sup>g</sup>	Not applicable	Not applicable/ 41.4	Not applicable		Not a	pplicable
Maximum metabolism rate in the liver (mg/hr/kg <sup>0.74</sup> ), low affinity pathway <sup>g</sup>	Not applicable	10.6	Not applicable		Not a	pplicable
Michaelis constant, lung metabolism	$2.5/3.52^{\rm h}$ (f)	Not	Not	Not applicable		1.04 <sup>i</sup>
(mg/L)	$1.8/4.07^{\rm h}$ (m)	applicable	applicable			
Maximum metabolism rate in the lung $(mg/hr/kg^{0.74})$	$27.4/4.65^{h}$ (f) $29.2/4.65^{h}$ (m)	Not applicable	Not applicable	Not applicable		0.17 <sup>1</sup>
Michaelis constant, RPT metabolism (mg/L)	N/A/1.32 (f) N/A/1.67 (m)	Not applicable	Not applicable	Not applicable	Not a	pplicable
Maximum metabolism rate in RPT (mg/hr/kg <sup>0.74</sup> )	N/A/21.8 (f) N/A/24.1(m)	Not applicable	Not applicable	Not applicable	Not a	pplicable

<sup>a</sup>Haddad *et al.* (2000). <sup>b</sup>Dennison *et al.* (2003). <sup>c</sup>Physiology from Gentry *et al.* (2004). <sup>d</sup>Haddad *et al.* (2001). <sup>e</sup>Dennison *et al.* (2005). <sup>f</sup>Kidney:air 68.43, brain:air 51.44, heart:air 61.16. <sup>g</sup>Estimated for this assessment (see text). <sup>h</sup>Case1/Case2 (see text). <sup>i</sup>Estimated from Saghir and Rick (2005).

The mouse PBPK model for ethylbenzene was developed by Nong *et al.* (2006). Mouse physiological parameters were obtained from the literature and partition coefficients were measured in vitro for blood (male and female) and tissues (male fat, muscle, liver, lung, brain, kidney, and heart) were measured. The maximal rate of hepatic metabolism (normalized by  $BW^{0.75}$ ) and Michaelis constant in uninduced mice was assumed to be equal to that in rats (Haddad et al., 2000, 2001). Parameter sets were developed for two approaches to estimating extrahepatic metabolism. In case 1, it is assumed that all extrahepatic metabolism takes place in the lung. In case 2, pulmonary metabolism was estimated by scaling the amounts of measured metabolites measured at the highest concentration tested in vitro (Saghir and Rick, 2005) and scaling based on microsomal protein content of the lung (as described under "Methods") and additional extrahepatic metabolism (VMAXR and KMR) was also assumed in RPT. For case 2, the whole-lung Vmax (normalized to body weight) was estimated using the mouse lung microsomal protein yield of Boogaard et al. (2000) and default adult tissue weight and body weight (Table P-1). By optimizing the fit to the blood time course of ethylbenzene in male and female mice exposed once to 75, 200, 500 or 1000 ppm ethylbenzene for 4 hrs (Charest-Tardif *et al.*, 2006), other metabolic parameters were determined (for case 1, pulmonary Vmax and KM; for case 2, pulmonary KM, and RPT Vmax and KM). These parameters were validated by comparison to additional blood time courses for mice exposed once (Charest-Tardif et al., 2006). For repeated exposure, liver metabolism was increased by 3x based on the fit to blood ethylbenzene concentration time courses for mice repeatedly exposed to 750 ppm ethylbenzene (Charest-Tardif et al., 2006). This adjustment was validated by comparison to the post exposure blood and tissue ethylbenzene concentrations measured by Fuciarelli (2000) in repeatedly-exposed mice.

The human PBPK model for ethylbenzene was developed by Tardif et al. (1997) using the same metabolic rates developed for rats with human-specific physiological parameters and a measured human blood:air partition coefficient. As noted above for the rat model, the metabolism parameters were subsequently modified slightly to optimize fit to data sets developed for mixtures (Haddad et al., 2000, 2001). Dennison et al. (2003) applied this same model (with the original values for metabolism parameters) to simulate "resting" conditions and modified alveolar ventilation rate, cardiac output, and blood flow distribution to simulate light work (50 W). Jang et al. (2001) applied the metabolism parameters determined by Tardif et al. (1997) to a seven-compartment PBPK model (lung, muscle and skin, fat, brain, kidneys, liver, and other tissues). The measured blood:air partition coefficient of Sato and Nakajima (1979) was used, but other tissue:air partition coefficients were estimated from the blood:air, olive oil:air and water:air partition coefficients, rather than using measured values. The presentation of the model is confusing because authors provided alveolar ventilation and cardiac output rates for both resting and 50W, but only provided blood flow rates (L/h) for resting, and did not say which activity level was used in the modeling. Because the Jang model was not tested against new data and the partition coefficients were estimated rather than measured, we did not test its performance against the available human data sets.

Sweeney and Gargas (2006) made minor adjustments to the human PBPK model for ethylbenzene in order to make predictions of lactational transfer of ethylbenzene to

children of ethylbenzene-exposed mothers. Details are provided in **Appendix N**. Due to the interest in the lung as a potential target organ for ethylbenzene toxicity (NTP, 1999; **Sections 7 and 8**), an estimate of human lung metabolism of ethylbenzene was made by scaling *in vitro* data (Saghir and Rick, 2005) and incorporated into the PBPK model. This estimate is discussed in greater detail below.

The validity of some of the partition coefficients (PC) used in the models was evaluated by comparison to additional data not used in the models.

Sensitivity analyses were conducted for key dose metrics used to derive toxicity reference values on the basis of effects observed in rodent studies (**Section 8**). The sensitivity of these dose metrics to alterations in parameter values for humans exposed to ethylbenzene at the RfC or RfD was also determined. These results were used to evaluate the adequacy of the toxicity reference values (which were derived for adults) for children.

## METHODS

A literature review was conducting using MEDLINE and TOXLINE. Some unpublished data was available from the sponsor and performing laboratory. Numerical data were provided by Kannan Krishnan (Tardif *et al.*, 1996, 1997 data) and Jim Dennison (Dennison *et al.*, 2003). Data from other publications were either taken from tables or estimated using Plot Digitizer. Model simulations were conducting using ACSL Math 11.8.4 (AEgis Technologies, Inc.).

Parameters for adult rats were taken from the model publications (Haddad *et al.*, 2000, Dennison *et al.*, 2003), with the exception of study-specific body weights, and the addition of a second, low-affinity metabolism pathway to the Krishnan model. The Michaelis constant (KM) for the low-affinity pathway was assumed equal to the average KM of the low affinity pathway as derived by Sams *et al.* (2004) for metabolism of ethylbenzene to 1-phenylethanol by human microsomes. The maximal rates of metabolism for the two pathways were determine by optimization of fit of the model to the blood concentrations of ethylbenzene measured in rats exposed to 50, 100, 200 ppm (Tardif *et al.*, 1996) or 500 ppm (unpublished data). Optimization was performed using ACSL Math, using the criterion of maximization of the Log Likelihood Function (LLF) using the relative error model, using the Nelder-Mead approach.

Body weight for postnatal day (PND) 22 Sprague-Dawley rat pups were estimated as equal to the PND 21 body weights (Faber *et al.*, 2006). Other anatomical and physiological parameters for PND 22 Sprague-Dawley rats (**Table P-1**) were estimated from data in Gentry *et al.* (2004). Fractional liver, and adipose tissue weights were taken from data collected for PND 22 rats. The fractional weight of the "slowly perfused" tissues (SPT) compartment was assumed to be the same as the sum of the fractional weights of the skin and muscles for 60-day old rats. Unperfused tissue was estimated as 9 percent of body weight; the volume of the rapidly-perfused tissues (RPT) compartment was estimated by difference (total body weight = sum of unperfused tissue, RPT, SPT, liver, and fat). Body weight-normalized total cardiac output (QCC) was estimated from

PND 22 rat data assuming scaling according to  $BW^{0.75}$ . Body weight-normalized total pulmonary ventilation rate was derived from PND 22 rat data, again assuming scaling according to  $BW^{0.75}$ ; alveolar ventilation was estimated as two-thirds of total pulmonary ventilation. Fractional blood flows (liver, adipose, muscle and skin) were taken from data for PND 60 rats; blood flow to the richly perfused tissues was calculated by difference, as the sum of the tissue flows must equal the total cardiac output. Blood:air and tissue:air partition coefficients for PND 22 rats were assumed to be the same as for adult rats.

All simulations for humans were conducted using the model parameters of Haddad *et al.* (2000) with the exception of data specified as having been collected under "light work" conditions and those involving lung dosimetry (i.e., lung cancer toxicity reference values). For the "light work" data set, the alveolar ventilation and blood flows of Dennison *et al.* (2005) were used with the metabolism parameters of Haddad *et al.* (2000). In order to develop dosimetry estimates for ethylbenzene metabolites potentially produced in the human lung, the rate of metabolism of ethylbenzene in the human lung was estimated. Saghir and Rick (2005) failed to detect any metabolites of ethylbenzene when human lung microsomes were incubated with 7500 ppm ethylbenzene in incubation vials. We assumed that each metabolite was present at the limit of quantitation. The whole-tissue rate (normalized to body weight) was then estimated using the human lung microsomal protein yield of Boogaard *et al.* (2000) and default adult tissue weight and body weight (**Table P-1**). The estimate of 0.17 mg/hr-kg<sup>0.74</sup> for the lung is small as compared to the value of 6.39 mg/hr-kg<sup>0.74</sup> assigned to the liver (Haddad *et al.*, 2000), consistent with the validity of neglecting human lung metabolism in the context of accurately modeling blood levels of ethylbenzene in humans exposed by inhalation.

No additional mouse pharmacokinetic data sets were available. We verified the reproducibility of the simulations of Nong *et al.* (2006) with the provided model code.

Sensitivity analyses were conducted by increasing input parameters by 1 percent and determining the change in the model output of interest. Normalized sensitivity coefficients (SC) were calculated as % change output/% change input.

## RESULTS

## Partition coefficients

Blood:air partition coefficients appear to have substantial species differences among mice, rats, and humans. Tardif *et al.* (1997) report a value of 28.0 for humans. The human blood:air partition coefficient of ethylbenzene has also been measured by Sato and Nakajima (1979) as 28.4. The blood air partition coefficient for mature rats (350 g) reported by Kumarathasan *et al.* (1998) (65) was somewhat higher than the value reported by Tardif *et al.* (1997) (42.7), but is similar to the female mouse value (65.4) (Nong *et al.*, 2006).

Kumarathasan *et al.* (1998) report rat liver:air and muscle:air PCs of 209 and 97 for 350 g rats, values which are 2.5x and 3.7 x higher, respectively, than the Tardif *et al.* (1997) values. The corresponding mouse tissue:air PCs (Nong *et al.*, 2006) are closer to the Tardif *et al.* (1997) values, suggesting that the discrepancies may be due to methodological differences rather than an age-related change.

Tardif et al (1997) reported a rat RPT:air partition coefficient of 60.3, but did not state the tissue of origin. Kumarathasan *et al.* (1998) report values of 102 and 115 for brain and kidney, which are both higher that the Tardif *et al.* (1997) RPT value. Meulenberg *et al.* (2003) report a brain:air PC of 79.2 for young adult male Wistar rats. Mouse RPT:air PCs range from 51 (brain) to 68 (kidney) (Nong *et al.*, 2006).

Tardif *et al.* (1997), Nong *et al.* (2006), and Pierce *et al.* (1996) report very similar adipose:air PCs of 1556, 1417, and 1764 for rats, mice, and human tissues, respectively. Kumarathasan *et al.* (1998) report a value of 2553.

With the exception of some of the Kumarathasan *et al.* (1998) partition coefficients (liver, muscle, and RPT), the measured partition coefficients are similar (within a factor of 2) among the studies. The values reported by Kumarathasan *et al.* (1998) are consistently higher than those measured by others. Kumarathasan *et al.* (1998) also reported tissue:blood partition coefficients for "young" rats (250 g), but in the absence of the blood:air PC, it is difficult to know how to interpret these ratios, in light of the discrepancies already noted between Kumarathasan *et al.* (1998) and other PC measurements.

Jang *et al.* (2001) used a measured human blood:air (Sato and Nakajima, 1979) and estimated tissue:air PCs. Their values are generally in the range of the experimental data for partition coefficients. Their estimated human muscle and skin:air PC was 52.7, roughly 2x higher than the measure rat muscle value (Tardif *et al.*, 1997), but similar to the measured mouse muscle value (Nong *et al.*, 2006).

In summary, the measured partition coefficients used in the models are generally consistent with other values reported in the literature; observed discrepancies may be due to methodological differences. The measured PCs of Tardif *et al.* (1997) were used in subsequent modeling efforts for humans and rats, and the measured mouse PCs of Nong *et al.* (2006) were used in modeling of that species.

### Refinement of the Krishnan Model

A second, low-affinity pathway for metabolism of ethylbenzene in the rat liver was added to the Krishnan model. The parameters are presented in **Table P-1**. The resultant model simulations are discussed below, under "Rat Model Evaluation."

### Rat Model Evaluations

The rat model simulations of various data sets (summarized in **Table P-2**) are depicted in **Figures P-2-12** and **Tables P-3-8**. The convention throughout the figures is that the Krishnan model simulations are depicted with heavy lines, the Dennison model predictions with thin lines. The Dennison model was not used for oral dosing predictions because optimization of the oral absorption rate constant by Krishnan and co-workers is necessarily coupled to the values of other parameters in their model.

### Inhalation studies

Dennison *et al.* (2003) determined the uptake of ethylbenzene by male F344 rats in a closed chamber uptake system. Initial efforts to reproduce this data with an estimated body weight of 0.31 kg were unsuccessful (the paper reported weights of 0.29 to 0.33 kg for 8-9 week old animals). The author provided simulations that matched the published figure, but were produced with a rat body weight of 0.22 kg. When a body weight of 0.22 kg was used with the other parameters as reported by Dennison *et al.* (2003), we were able to reproduce an accurate simulation. The parameter values of the Krishnan model provided an equivalent fit at higher concentrations, but underpredicted chamber disappearance of ethylbenzene toward the end of the experiment (**Figure P-2**).

**Figure P-3**, panels a, b, and c show how the two models predict the blood concentrations reported by Tardif *et al.* (1997) for male Sprague-Dawley rats. Panel d shows the predictions of an unpublished set of 500 ppm data collected by the same laboratory. As expected, the Krishnan model reproduced the data in **Figure P-3 a-c** accurately—this model was initially calibrated using this data set. The Dennison model consistently underpredicts these blood concentrations. Note that neither model successfully predicted the 500 ppm data. The Krishnan model overpredicted blood concentrations from the 500 ppm exposure at all times. The Dennison model accurately predicted the first post-exposure point, but the blood ethylbenzene concentration predictions then decline more rapidly than indicated by the experimental data. The addition of a second metabolism pathway (**Figure P-3e**, light lines) improved the fit to the blood data at a higher concentration (500 ppm) without substantially altering the fit at lower concentrations (representative simulation at 200 ppm shown).

Cappaert *et al.* (2002) exposed Wag/Rij (Wistar-derived) rats to 500 ppm ethylbenzene for 8 hrs per day for 1 or 3 days. Measured blood concentrations were significantly different on days 1 and 3 (**Table P-3**). Both the Krishnan and Dennison models overpredicted the Day 1 concentrations by approximately a factor of 2. The degree of overprediction was much greater on Day 3. It has been determined that exposure to sufficiently high concentrations of ethylbenzene initially induces increased expression of CYP 2E1 and 2B1/2 in male Holtzman rats, leading to more rapid clearance of ethylbenzene. However, this induction is transient, and mRNA expression levels return to approximately baseline levels in approximately 3 days (Bergeron *et al.*, 1999).

Author	Strain	Lifestage	Gender	Exposure	Dose Metric	Figure or Summary Table Number
Dennison et al. (2003)	F344	Adult	Male	Starting concentration 1700 ppm	Closed chamber air concentration	Figure P-2
Tardif <i>et al.</i> (1996)	SD	Adult	Male	50, 100, 200, 500 ppm	Ethylbenzene concentration in blood	Figure P-3
Cappaert et al. (2002)	Wag/Rij (Wistar- derived)	Adult	Male	500 ppm	Ethylbenzene concentration in blood	Table P-3
Romer <i>et al.</i> (1986)	SD	Adult	Female	180 ppm	Ethylbenzene concentration in blood	Figure P-4
Freundt <i>et al.</i> (1989)	SD	Adult	Female	120, 240, 350, 650 ppm	Ethylbenzene concentration in blood	Figure P-4
Fuciarelli (2000)	F344	Adult	Male and Female	75, 750 ppm	Ethylbenzene concentration in blood, mesenteric rat, liver, lung	Tables P-4-7, Figures P-5 and 6
Engstrom et al. (1985)	Wistar	Adult	Male	0, 50, 300, 600 ppm	Ethylbenzene in perirenal fat , amount of urinary metabolites	Figures P-7 and 8
Chin et al. (1980)	Wistar	Young adult (100-120 g)	Male	230 ppm	Urine, feces, and expired air	Table P-8
Faber <i>et al.</i> (2006)	SD	PPD/PND 22	Male and Female	0, 25, 100, 500 ppm	Ethylbenzene concentration in blood	Figure P-9
Krishnan (2002)	SD	Adult	Female	180 (1x), 206.5 (3x, two- hour spacing) mg/kg in corn oil	Ethylbenzene concentration in blood	Figures P-10 and 11
Faber <i>et al.</i> (2006)	SD	PPD 4	Female	26, 90, 342 mg/kg in corn oil (3x, two-hour spacing)	Ethylbenzene concentration in blood	Figure P-12

# **Table P-2.** Summary of Rat Studies used to Evaluate PBPK Model Performance

Appendix P



**Figure P-2.** Fits of models to closed chamber uptake of 1700 ppm ethylbenzene by male F344 rats. Symbols—Dennison *et al.*, 2003. Model of Dennison *et al.* (2003) —thin line. Model of Haddad *et al.* (2000) (Krishnan model)—heavy line.





**Figure P-3.** Fit of models to post-exposure blood concentrations in ethylbenzeneexposed male Sprague-Dawley rats. Symbols—Tardif *et al.* (1996),  $\pm$  standard deviation. (a) 50 ppm (b) 100 ppm (c) 200 ppm; unpublished data (d) 500 ppm; (e) 200 and 500 ppm. Model of Dennison *et al.* (2003) —thin line. Model of Haddad *et al.* (2000) (Krishnan model)—dark, heavy line. Current modification of Krishnan model (Sweeney model)—light-colored heavy line (Figure 3e only)

**Table P-3.** Ethylbenzene blood concentrations (mg/L) at the end of daily 8-hr exposures of Wag/Rij Rats to 500 ppm ethylbenzene (Cappaert *et al.* 2002).

	Mean ± Standard Deviation	Krishnan Model	Dennison Model
Day 1	$23.2\pm1.5$	53.7	40.3
Day 3	$5.7 \pm 0.6$	53.7	40.3

Römer *et al.* (1986) and Freundt *et al.* (1986) exposed female Sprague-Dawley rats to 120 to 650 ppm ethylbenzene for two hours, and then measured ethylbenzene in collected blood. The Dennison model provides an accurate prediction of the blood concentrations. While the Krishnan model overpredicts blood concentrations at two hours, predictions of blood concentrations at approximately 2.05 hrs (3 minutes after cessation of exposure) more closely approximate the measured values (**Figure P-4**). Due to the difficulty of immediately collecting the blood, it may be more appropriate to compare the experimental data to the 2.05 hr predictions.

Appendix P



**Figure P-4.** Fit of models to end-of-exposure blood concentrations in ethylbenzeneexposed female Sprague-Dawley rats. Symbols—Triangles, Freundt *et al.* (1989), 120, 240, 350 or 650 ppm; diamond, Römer *et al.* (1986), 180 ppm. Model of Dennison *et al.* (2003) —thin line. Model of Haddad *et al.* (2000) (Krishnan model)—solid, heavy line = end of exposure prediction, dashed heavy line = 0.05 hr (3 minutes) postexposure estimate.

Fuciarelli (2000) exposed male and female F344 rats to 0, 75, or 750 ppm ethylbenzene by inhalation for 6 hours/day, 5 days per week for up to 12 days. At the end of days 1, 4, and 12, blood, lung, liver, and mesenteric fat were collected within 20 minutes for ethylbenzene measurement. Also, these same tissues were collected for a postexposure time course on day 12. The comparative data for days 1, 4, and 12 are presented in **Tables P-4-7**, and the time course data are presented in **Figures P-5 and 6**. Neither model provided adequate prediction of the 750-ppm data. At 75 ppm, the Dennison model more accurately predicted ethylbenzene concentrations in blood and tissues at the end of exposure than the Krishnan model. The Dennison model generally predicted postexposure declines that were less steep than the Krishnan model and were more in keeping with the trends in the data.

	Male	e Rat	Female Rat	
	75 ppm	750 ppm	75 ppm	750 ppm
Day 1 <sup>a</sup>	$0.55\pm0.06$	$19.6 \pm 3.2$	$0.30\pm0.01$	$19.0\pm4.8$
Day 4	$0.58\pm0.11$	$9.9 \pm 2.7$	$0.27\pm0.04$	$12.2 \pm 1.4$
Day 12	$0.64\pm0.06$	$12.4\pm0.5$	$0.33\pm0.13$	$13.3 \pm 2.7$
Krishnan	0.99 - 2.2	56.3 - 73.9	1.0 - 2.3	59.4 - 78.1
Model <sup>b</sup>				
Dennison	0.38 - 1.1	41.7 - 57.9	0.37 – 1.1	44.1 - 61.4
Model				

**Table P-4.** Ethylbenzene blood concentrations (mg/L) at the end of daily 6-hr exposures of F344 Rats to 75 or 750 ppm ethylbenzene (Fuciarelli, 2000).

<sup>a</sup>Experimental data (Fuciarelli, 2000) reported as mean  $\pm$  standard deviation (n = 3) <sup>b</sup>Model prediction range is for the period 0-20 minutes postexposure

**Table P-5.** Concentrations of ethylbenzene in mesenteric fat (mg/L) at the end of daily 6-hr exposures of F344 Rats to 75 or 750 ppm ethylbenzene (Fuciarelli, 2000).

	Male	e Rat	Female Rat		
	75 ppm	750 ppm	75 ppm	750 ppm	
Day 1 <sup>a</sup>	$18.5\pm4.5$	$518\pm256$	$17.3 \pm 2.9$	$1046\pm578$	
Day 4	$36.2 \pm 11.8$	$201 \pm 65$	$16.9\pm9.3$	$515\pm175$	
Day 12	$20.3\pm2.5$	$173 \pm 57$	$14.2\pm7.6$	$410\pm412$	
Krishnan	76.3 - 84.9	2343 - 2387	77.5 - 87.7	2505 - 2568	
Model <sup>b</sup>					
Dennison	40.3 - 44.1	1719 - 1724	40.9 - 45.4	1862 - 1876	
Model					

<sup>a</sup>Experimental data (Fuciarelli, 2000) reported as mean  $\pm$  standard deviation (n = 3) <sup>b</sup>Model prediction range is for the period 0-20 minutes postexposure

**Table P-6.** Concentrations of ethylbenzene in liver (mg/L) at the end of daily 6-hr exposures of F344 Rats to 75 or 750 ppm ethylbenzene (Fuciarelli, 2000).

	Male	e Rat	Female Rat		
	75 ppm	750 ppm	75 ppm	750 ppm	
Day 1 <sup>a</sup>	$0.76\pm0.25$	$44.7\pm10.8$	$0.24 \pm 0.9$	$46.2\pm10.8$	
Day 4	$0.67\pm0.11$	$18.0\pm5.0$	$0.14\pm0.12$	$22.1 \pm 4.3$	
Day 12	$0.72\pm0.19$	$25.6\pm3.2$	$0.16\pm0.04$	$27.2 \pm 5.4$	
Krishnan	0.89 - 2.9	105 - 144	0.9 - 3.0	111 - 152	
Model <sup>b</sup>					
Dennison	0.03 - 0.2	76 – 111	0.03 - 0.2	80-118	
Model					

<sup>a</sup>Experimental data (Fuciarelli, 2000) reported as mean  $\pm$  standard deviation (n = 3) <sup>b</sup>Model prediction range is for the period 0-20 minutes postexposure

	Male	e Rat	Female Rat	
	75 ppm	750 ppm	75 ppm	750 ppm
Day 1 <sup>a</sup>	$2.33\pm0.60$	$38.7 \pm 24.4$	$0.41\pm0.07$	$19.0\pm13.2$
Day 4	$0.76\pm0.05$	$7.0 \pm 0.3$	$1.24\pm0.94$	$7.2 \pm 2.5$
Day 12	$1.91 \pm 1.07$	$9.0 \pm 0.04$	$1.04\pm0.45$	$9.7\pm1.8$
Krishnan	1.28 - 2.5	58.1 - 75.4	1.3 - 2.5	61.2 – 79.5
Model <sup>b</sup>				
Dennison	0.63 – 1.3	43.5 - 59.4	0.62 – 1.3	45.8 - 62.8
Model				

**Table P-7.** Concentrations of ethylbenzene in lung (mg/L) at the end of daily 6-hr exposures of F344 Rats to 75 or 750 ppm ethylbenzene (Fuciarelli, 2000).

<sup>a</sup>Experimental data (Fuciarelli, 2000) reported as mean  $\pm$  standard deviation (n = 3) <sup>b</sup>Model prediction range is for the period 0-20 minutes postexposure. Arterial blood prediction used as surrogate for lung.

Appendix P



**Figure P-5.** Fit of models to post-exposure blood concentrations in ethylbenzeneexposed male F344 rats. Symbols—Fuciarelli (2000), 75 or 750 ppm. (a) venous blood (b) mesenteric fat (c) liver (d) lung/arterial blood. Model of Dennison *et al.* (2003) thin line. Model of Haddad *et al.* (2000) (Krishnan model)—heavy line.

Appendix P



**Figure P-6.** Fit of models to post-exposure blood concentrations in ethylbenzeneexposed female F344 rats. Symbols—Fuciarelli (2000), 75 or 750 ppm. (a) venous blood (b) mesenteric fat (c) liver (d) lung/arterial blood. Model of Dennison *et al.* (2003) —thin line. Model of Haddad *et al.* (2000) (Krishnan model)—heavy line.

Engstrom *et al.* (1985) measured ethylbenzene in perirenal fat of male Wistar rats exposed to 50, 300 or 600 ppm ethylbenzene for 2, 5, 9, or 16 weeks. Measured fat concentrations of ethylbenzene were generally consistent throughout the exposure period for a given exposure concentration of ethylbenzene. Predictions of both the Krishnan and Dennison models were substantially higher than the reported values (**Figure P-7**). We attribute this discrepancy to the difficulties in analyzing concentrations in adipose tissue. Analyte may be lost to off-gasing during excision of the tissue after sacrificing the animal or losses may occur during homogenization. Total amounts excreted in urine were similar to the amounts predicted by both models (**Figure P-8**).

Appendix P



**Figure P-7.** Fit of models to four-hour perirenal fat concentrations in ethylbenzeneexposed male Wistar rats. Symbols—Engstrom *et al.* (1985), 50, 300, or 600 ppm. Model of Dennison *et al.* (2003) —thin line. Model of Haddad *et al.* (2000) (Krishnan model)—heavy line.

Appendix P



**Figure P-8.** Fit of models to 24 hr urinary metabolites eliminated by ethylbenzeneexposed male Wistar rats. Symbols—Engstrom *et al.* (1985), 50, 300, or 600 ppm. Model of Dennison *et al.* (2003)—thin line. Model of Haddad *et al.* (2000) (Krishnan model)—heavy line.

Chin *et al.* (1980) conducted a study in which 110-g male Wistar rats were exposed to 230 ppm radiolabeled ethylbenzene for 6 hrs and urine, feces, and expired air were collected. The authors report that 16 mg ethylbenzene per rat was "retained", calculating this number from the mass of chemical needed to maintain target concentrations in the test chamber. Of this 16 mg, 91.7 percent was recovered (14.7 mg), with 13.3 mg recovered in urine and feces and 1.3 mg as "expired gases" other than carbon dioxide (presumably parent ethylbenzene). The Krishnan and Dennison models performed equally well at predicting the total ethylbenzene retained, but the Krishnan model more accurately predicted the postexposed exhalation of ethylbenzene (**Table P-8**).

Experimental Data	Chin et al. (1980)	Krishnan Model	Dennison Model
Retained (mg)	16	12.2	11.6
Post Exposure Exhalation (mg)	1.3	1.5	0.4
Metabolites (mg)	13.3	10.7	11.2

Table P-8. Disposition of 230 ppm ethylbenzene in Wistar rats (Chin et al., 1980)

Faber *et al.* (2006) performed limited inhalation kinetics evaluations in postpartum/postnatal day (PPD/PND) 22 F1 dams and F2 pups as part of a twogeneration study conducted in Sprague-Dawley rats exposed to 0, 25, 100, or 500 ppm ethylbenzene for 6 h/d. Blood was sampled 1 hr after completion of exposure. For the dams, the model predictions bracket the measured blood concentrations at 25 and 100 ppm, but both models overpredict blood ethylbenzene at 500 ppm. For pups, both models substantially overpredict blood ethylbenzene at 25 ppm (**Figure P-9**).



**Figure P-9.** Fit of models to one-hour postexposure blood concentrations in ethylbenzene-exposed PND/PPD 22 Sprague-Dawley rats. Symbols: diamonds = dams, triangles = pups; Faber *et al.* (2006), 25, 100, or 500 ppm. Model of Dennison *et al.* (2003)—thin lines. Model of Haddad *et al.* (2000) (Krishnan model)—heavy lines. Dams: solid lines; pups, dashed lines.

#### Gavage Data

The oral uptake rate of ethylbenzene from a corn oil vehicle was estimated by Krishnan (2002) and reported by Faber *et al.* (2006). Blood was collected for up to 26 hours after administering a single 180 mg/kg dose of ethylbenzene in corn oil to adult female rats. The oral absorption rate was estimated by adjusting the parameter to best match the data (**Figure P-10**). The model was tested against blood concentration data collected in adult female rats that received three gavage doses of 206.5 mg/kg at two-hour intervals (unpublished data, Krishnan, 2002). The model somewhat overpredicted all but the earliest measured blood concentrations (**Figure P-11**).



**Figure P-10.** Fit of Krishnan model to blood concentrations in female Sprague-Dawley rats receiving a single 180 mg/kg dose of ethylbenzene in corn oil. Figure reproduced from Krishnan (2002); data referred to, but not shown in Faber *et al.* (2006).

Appendix P



**Figure P-11.** Fit of Krishnan model (line) to blood concentrations in female Sprague-Dawley rats receiving a three 206.5 mg/kg doses of ethylbenzene in corn oil with twohour spacing (symbols). Figure reproduced from Krishnan (2002).

Faber *et al.* (2006) performed limited oral kinetics evaluations in PPD 4 F1 dams as part of a two-generation study conducted in Sprague-Dawley rats. Dams were dosed 3 times in one day, with two-hour spacing between doses, for total daily doses of 26, 90, and 342 mg/kg in corn oil. Blood samples were collected 1 hour after the last dose of the day. Ethylbenzene was not found above the level of detection in suckling pup blood. The Krishnan model slightly underpredicted the concentrations of ethylbenzene in dam blood for the low- and mid- dose groups, but slightly overpredicted the blood concentration for the high dose dams (**Figure P-12**).

Appendix P



**Figure P-12.** Fit of Krishnan model (line) to blood concentrations in PND 4 Sprague-Dawley dams measured one hour after receiving the last of three equal doses (two-hour spacing) of ethylbenzene in corn oil. Symbols—Faber *et al.* (2006); 26, 90, or 342 mg/kg per dose.

#### Mouse Model Evaluation

The mouse PBPK model described in the manuscript (Nong *et al.*, 2006) tested the model against all relevant available datasets. We were able to recreate the simulations as presented by Nong *et al.* (2006) (not shown). We attempted to duplicate the optimization of lung metabolic parameters as described by Nong *et al.* (2006). Our optimized parameter values were generally within 20% of those reported by Nong *et al.* (2006).

#### Human Model Evaluation

The human studies used here to evaluate the performance of the Haddad *et al.* (2000) model are summarized in **Table P-5**. The PBPK model has previously been used by Krishnan (2001) to interpret the results of various biomonitoring studies in light of ambient exposure concentrations in different environments. Krishnan's results are reported separately in **Appendix R**.

Author	Exposure	Dose Metric	Figure Number
Tardif <i>et al</i> . (1997)	33 ppm	Ethylbenzene concentration in blood and alveolar air	P-13
Knecht et al. (2000)	25 ppm (rest), 100 ppm (rest and 50 W)	Ethylbenzene concentration in blood	P-14
Kawai et al. (1992)	1.28-5.7 ppm 8-hr TWA	Ethylbenzene concentration in blood	P-15
Engstrom et al. (1984)	150 ppm	Amount of urinary metabolites	None
Gromiec and Piotrowski (1984)	4.1, 7.8, 18, or 46 ppm	Fractional retention, amount exhaled	P-16

Table P-5. Summary of Studies Used to Evaluate Human PBPK Model Performanc	e
----------------------------------------------------------------------------	---

The model accurately predicted both the blood and alveolar concentrations of ethylbenzene in Tardif *et al.* (1997) (**Figure P-13a and b**). This result is to be expected, since the parameters in the Haddad *et al.* (2000) model differ only slightly from those in Tardif *et al.* (1997).



(a)

Appendix P



(b)

**Figure P-13.** Fit of Krishnan model (line) to blood (a) and alveolar air (b) concentrations in male human volunteers exposed to 33 ppm ethylbenzene (Tardif *et al.*, 1997).

The model predictions of the blood concentration data of Knecht *et al.* (2000) were generally about double the measured concentrations (**Figure P-14**). Knecht *et al.* (2000) report performing the blood collection in a "clean area"; it is unclear how much of a delay this produced, but this may account for some of the difference between predicted and measured values.

Appendix P



**Figure P-14.** Fit of Krishnan model (lines) to blood concentrations in human volunteers exposed to 25 ppm ethylbenzene while at rest (diamonds) or 100 ppm ethylbenzene while at rest (triangles) or working at a level of 50 W (x). Knecht *et al.* (2000).

Kawai *et al.* (1992) determined 8-hr TWA exposure levels for factory workers exposed to a mixture of three xylene isomers and ethylbenzene and measured cubital vein blood ethylbenzene in samples taken within 20 minutes of the end of an 8-hr shift. For these simulations, it was assumed that the exposure was constant over the eight-hour period and that co-exposure to the xylenes (mean xylenes: 8 ppm, maximum, 27 ppm) did not have a significant effect on ethylbenzene kinetics, consistent with the findings of Tardif *et al.* (1997). Overall, the model did a good job in predicting this data set (**Figure P-15**), given the uncertainties in the actual exposure patterns of the workers.

Appendix P



**Figure P-15.** Fit of Krishnan model to blood concentrations in workers exposed to ethylbenzene and mixed xylenes. Heavy line: predicted end of exposure blood concentration. Light line: predicted blood concentration 20 minutes after the end of exposure. Symbols: Kawai *et al.* (1992).

Gromiec and Piotrowski (1984) measured the "retention" of ethylbenzene by volunteers exposed to 4.1 to 46 ppm ethylbenzene. Retention was calculated by the authors based on the ratio of exhaled to inhaled concentration at different times during exposure. Gromiec and Piotrowski also determined the total amount exhaled by the volunteers. Using the midpoint of the ranges provided for each exposure level, the average "retention", and known starting concentrations, estimated alveolar ventilation rates of ~14 L/hr/kg<sup>0.75</sup> were calculated, which were slightly lower than the Tardif *et al.* (1997) default values. While the "retention" is sensitive to the ratio of alveolar to total ventilation, the fit of the model to the data is supportive of the validity of the model (**Figure P-16**).

Appendix P



**Figure P-16.** Fit of Krishnan model (line) to fractional retention of ethylbenzene by human volunteers exposed to 4.1, 7.8, 18, or 46 ppm ethylbenzene (results averaged across exposures). Symbols: Gromiec and Piotrowski (1984).

Engstrom *et al.* (1984) reported mean urinary excretion of  $619 \pm 69$  mg-equivalents of ethylbenzene in a 24-hour period in four human volunteers exposed to 150 ppm ethylbenzene for four hours. The model prediction of 510 mg metabolized is reasonably accurate.

#### Sensitivity Analyses

Sensitivity analyses were conducted to determine the impact of altering model parameters on key dose metrics used in toxicity reference value derivation. The sensitivity of parameters in the human model was determined with respect to the area under the ethylbenzene concentration vs. time curve in richly perfused tissue (AUCR) and amount of ethylbenzene metabolized per unit volume of liver tissue (AM/VL). These computations cover the period of one week (the difference between AUCR or AM/VL at t=504 hrs and the value at t=336 hrs) and were conducted for continuous exposure to 0.8 ppm in air, or ingestion of 0.5 mg/kg bwt/day, the proposed noncancer RfC and RfD used in this assessment (Section 8). A sensitivity analysis was conducted for the mouse AM/VL for one 6-hr exposure to 75 ppm ethylbenzene, using the parameter set for repeatedly-exposed male mice, assuming no metabolism occurs in the richly perfused tissues. A sensitivity analysis for the mouse amount metabolized in the lung per unit volume of lung (AMP)/VP for one 6-hr exposure to 75 ppm ethylbenzene, using the parameter set for repeatedly-exposed male mice, assuming metabolism occurs in the richly perfused tissues. A sensitivity analysis of the AUCR determined for rats exposed to 200 ppm for 6 hrs was conducted, as was for sensitivity of AM/VL after gavage dosing of a divided dose of 75 mg/kg bwt/day (per Mellert et al., 2004). Results are summarized in Table P-6.

Parameter <sup>a</sup>	Hur	nan	Human	Ingestion	Mouse I	nhalation	Rat	Rat
	Inhal	ation <sup>b</sup>		Ū.			Inhalation	Ingestion
	AUCR	AM/VL	AUCR	AM/VL	AM/VL	AMP/VP	AUCR	AM/VL
Body weight	< 0.05	-0.25	-0.25	< 0.05	-0.26	-0.26	-0.06	< 0.05
Alveolar	0.81	0.8	-0.2	-0.07	1.1	0.87	1.2	-0.07
ventilation								
Cardiac output	-0.45	0.11	0.11	< 0.05	0.44	-0.40	-0.11	< 0.05
Fractional liver	< 0.05	-0.99	< 0.05	-0.99	-0.99	< 0.05	< 0.05	-0.99
volume								
Fractional lung	< 0.05	< 0.05	< 0.05	< 0.05	< 0.05	-0.99	< 0.05	< 0.05
volume								
Fractional liver	-0.45	0.11	0.11	< 0.05	0.44	< 0.05	-0.11	< 0.05
blood flow								
Fractional	< 0.05	< 0.05	< 0.05	< 0.05	< 0.05	0.05	< 0.05	< 0.05
adipose blood								
flow								
Fractional	< 0.05	< 0.05	< 0.05	< 0.05	< 0.05	0.09	< 0.05	< 0.05
slowly								
perfused tissue								
blood flow		0.4.0						0.00
Blood:air	-0.8	0.19	-0.80	0.07	< 0.05	< 0.05	-0.39	0.08
partition								
coefficient	.0.07	.0.07	.0.07	0.05	0.05	.0.05	0.10	0.05
Adipose:air	<0.05	< 0.05	< 0.05	<0.05	<0.05	<0.05	-0.19	<0.05
partition								
coefficient	1	.0.07	1	.0.07	0.05	.0.07	1	0.05
Richly	1	<0.05	1	<0.05	<0.05	<0.05	1	<0.05
(DDT) wir								
(RPI):air								
partition								
VM (liver	0.25	0.095	0.01	0.095	0.22	0.00	0.12	0.07
high offinity)	0.55	-0.085	0.91	-0.085	-0.55	0.09	0.15	-0.07
Vmax (liver	0.35	0.085	0.01	0.85	0.30	0.13	0.64	0.12
high affinity)	-0.55	0.085	-0.91	0.85	0.39	-0.15	-0.04	0.12
KM (liver low	N/A	N/A	N/A	N/A	N/A	N/A	0.14	<0.05
affinity)	1 <b>\</b> /A	11/1	11/1	$\mathbf{N}/\mathbf{A}$	11/17	11/A	0.14	<0.05
Vmax (liver	N/A	N/A	N/A	N/A	N/A	N/A	0.16	<0.05
low affinity)	$\mathbf{N}/\mathbf{A}$	$\mathbf{N}/\mathbf{A}$	1N/A	1N/A	IN/A	1N/A	-0.10	<0.05
KM (Lung)	N/A	N/A	N/A	N/A	0.74	-0.73	N/A	N/A
Vmax (lung)	$N/\Delta$	$N/\Delta$	$N/\Lambda$	$N/\Delta$	-0.92	0.75	N/A	N/A
KM (RPT)	$N/\Delta$	$N/\Delta$	$N/\Lambda$	$N/\Delta$	-0.92 N/Δ	0.09	N/A	N/A
$\frac{1}{1} \frac{1}{1} \frac{1}$	N/A	N/A	N/A	N/A	N/A	_0.20	N/A	N/A N/A
Concentration	1	1	1	1	11	0.024	1.5/	0.95
or Doso	1	1	1	1	1.1	0.92	1.34	0.95

Table P-6.	Sensitivity	Coefficients fo	or PBPK	Model (	Dutputs
	~~~~~~~~~~				

<sup>a</sup>For parameters not listed, the sensitivity was less than 0.05 for all tested scenarios. <sup>b</sup>Scenarios (exposure level, duration, etc.) are described above in the text.

The value of AUCR for rats inhaling 200 ppm ethylbenzene has a linear relationship to the RPT partition coefficient (Table P-6) and blood concentration. The confidence in AUCR calculations is thus essentially the same as confidence in the fit of the model to the blood concentration. Since the model parameterization is based on the fit to rat blood concentrations, the reliability of AUCR predictions, and their use in dose-response relationship evaluation, is thus high. The AM/VL values for rats ingesting ethylbenzene have minimal sensitivity to any optimized parameters at the test dose (75 mg/kg), because any portion of the dose that is not exhaled will eventually be metabolized in the liver. AM/VL values in mice, however, were sensitive to optimized parameters (lung metabolism), and do not have such a direct relationship to a quantity used for model optimization as the rat AUCR values. The parameter set used for the derivation of the RfC based on male mouse liver effects conservatively assumes that all extrahepatic metabolism occurs in the lung. With respect to liver dosimetry, the placement of extrahepatic metabolism in the lung (rather than richly perfused tissues) modestly reduces delivery of ethylbenzene to the liver via a first-pass effect of removal in the lung. Estimated ethylbenzene delivery to the liver was greater when some RPT metabolism was incorporated because some extrahepatic metabolism is parallel to the liver metabolism, rather than occurring entirely in the "first pass" through the lung.

The human sensitivity analyses were aimed at evaluating the adequacy of selected uncertainty factor for human variability (UFH), specifically the total value of 10, which may be subdivided into equal pharmacokinetic (UFH<sub>PK</sub>) and pharmacodynamic portions of 3.2 (3.2 x 3.2 = -10). Considering that the toxicity reference values were derived using the adult human parameter set (Table P-1) but applied to both children and adults (Section 8), interest lies primarily with sensitive parameters known or anticipated to differ between adults and children, with the focus on infants, who differ the most from adults. Clearly, body weight differs between adults and infants, as does bodyweightnormalized inhalation rate (Section 6). Alveolar ventilation was estimated as 60% of total ventilation reported in Section 6. The bodyweight-normalized cardiac output rate estimate was derived from data for newborns of Heymann et al. (1981). Liver volume of children age 0-12 months, as reported by ICRP (1975), was found to be essentially identical to that in adults, when normalized to bodyweight. No information is available on age-related changes in liver blood flow, the ethylbenzene blood:air and RPT:air partition coefficients, and rate of ethylbenzene metabolism. Fractional liver blood flow and partition coefficients were considered age- and bodyweight-independent. Expression of CYP 2E1, which is believed to contribute to human liver metabolism of ethylbenzene (Sams et al., 2004), is lower in children than adults (Johnsrud et al., 2003), but the ontogeny of other enzymes that contribute to human liver ethylbenzene metabolism is not as well known. The sublinear bodyweight-dependence of human liver ethylbenzene metabolism is assumed to sufficiently represent the potentially lower capacity of the infant liver to metabolize ethylbenzene. Using the infant-specific bodyweight, inhalation rate, and cardiac output, the same exposure scenarios and dose metrics used for the sensitivity analysis (Table P-6) were used to calculate-infant-specific dose metrics and child/adult dose ratios. For AUCR, the child/adult dose ratios were both less than 1 (0.60 and 0.93 for ingestion and inhalation, respectively); likewise, the child/adult ratio for AM/VL predictions by the ingestion route is 0.97, indicating that the UFH<sub>PK</sub> of 3.2 is

clearly adequate to protect children in these cases. The child/adult ratio for AM/VL predictions by the inhalation route is 2.2. Dividing the total UFH<sub>PK</sub> of 3.2 by the child/adult ratio of 2.2 leaves a residual value of 1.5 as the acceptable pharmacokinetic variability/uncertainty in children, beyond that accounted for by the use of child specific parameters (bodyweight, ventilation, and cardiac output) and bodyweight-normalized liver metabolism. Given the low sensitivity of the remaining parameters (0.11 for liver blood flow, 0.19 for blood:air partition coefficient), the total UFH<sub>PK</sub> of 3.2 appears adequate.

# DISCUSSION

For simulations of kinetics in Sprague-Dawley rats, the model of Krishnan and colleagues is preferred over the Dennison model because it more accurately predicts blood levels of ethylbenzene than does the Dennison model, particularly the Tardif et al. (1997) data set that was originally used to parameterize the Krishnan model. There are, however, limitations to the circumstances under which the Krishnan rat model can be applied reliably. The model does not account for transient induction of mRNA of ethylbenzene metabolizing enzymes in rats (return to baseline after 3 days) (Bergeron et al., 1999), so kinetics in rats that have been exposed to ethylbenzene for 2-3 days may not be accurately represented by the model. The model also generally underestimated metabolism at higher concentrations of ethylbenzene, producing overestimates in blood concentrations (generally <2-fold differences between measured and predicted blood concentrations under 650 ppm). The addition of a second, low affinity pathway improved predictions of blood concentrations at higher exposures. Also, the model predictions for PND 22 rat pups are not within the desired range of accuracy (~within a factor of 2). The Krishnan model can be used with high confidence for adult SD rats at concentrations at or below 200 ppm, moderate-to-high confidence for adult SD rats between 200 and 650 ppm. The oral model can be used with confidence for doses up to 180 mg/kg.

The Dennison model produced a superior fit to data sets collected using F344 rats, as compared to the Krishnan model performance. The F344 rat data sets were the closed chamber data (used to derive the Dennison metabolic parameters) and the Fuciarelli (2000) toxicokinetic data. Similar to the results for SD rats, the fit to the blood and tissue concentration data at high concentration (750 ppm) was poor. The Dennison model can be used with moderate confidence for F344 rats at low to intermediate concentrations, but cannot be confidently used for high concentrations. However, none of the key studies in the VCCEP risk assessment (**Section 8**) require simulation of toxicokinetics in F344 rats.

The lack of comparable toxicokinetic data sets preclude direct comparisons between F344 and Sprague-Dawley rats, but the general lack of success in applying the F344derived model to the Sprague-Dawley data and vice versa suggest that there may be strain differences with respect to the disposition of ethylbenzene. Given that there is some evidence for strain differences based on the modeling of F344 and Sprague-Dawley rats, and toxicity testing has been done in other strains as well, the question of which model to use for other strains of rats needs to be considered. Of greatest relevance to the current effort is consideration of Wistar rats, which were used in the key oral noncancer study (Mellert *et al.*, 2004). Based on the study urinary excretion of metabolites by Wistar rats, as reported by Engstrom *et al.* (1985), the models Krishnan and Dennison models are essentially equally successful at reproducing the data. Likewise, the two models are equally successful at predicting the amount of metabolism by Wistar rats in Chin *et al.* (1980). The Krishnan model, however, performed significantly better in predicting the post exposure exhalation of ethylbenzene measured in Chin *et al.* (1980). Based on this evaluation, we recommend the use of the Krishnan model for Wistar rats.

The mouse model (Nong *et al.*, 2006) adequately describes the blood and tissue kinetics of ethylbenzene in mice exposed to 75 to 750 ppm ethylbenzene in single or repeated exposures. Nong *et al.* (2006) have noted uncertainty with regard to the precise location of the extensive extrahepatic metabolism that is evident for ethylbenzene-exposed mice. This model can be confidently used to estimate blood and tissue ethylbenzene concentrations, and liver and whole-body metabolism for acute and repeated exposures up to 750 ppm ethylbenzene. The development of alternative descriptions of extrahepatic metabolism allowed for conservative estimation of lung metabolism for acute and repeated exposures up to 750 ppm.

The human model assumes a body weight-normalized metabolic rate equivalent to that determined for rats (Tardif *et al.*, 1997). Although this assumption was initially validated only against blood and breath data from a 33-ppm exposure, the model was found to predict data from low level occupational exposures (blood concentrations after 1.3-5.7 ppm, 8 hr-TWA exposures) and higher concentration volunteer exposures (excretion of urinary metabolites after 150 ppm exposure) with acceptable accuracy. Based on the ability of the model to reproduce blood concentrations from the low-level, occupational exposures, the PBPK model can be used with high confidence for humans exposed to ethylbenzene at all exposure levels expected to be relevant to the VCCEP analyses.

### REFERENCES

Bergeron, R.M., Desai, K., Serron, S.C., Cawley, G.F., Eyer, C.S., and Backes, W.L. (1999). Changes in the expression of cytochrome P450s 2B1, 2B2, 2E1, and 2C11 in response to daily aromatic hydrocarbon treatment. *Toxicol. Appl. Pharmacol.* **157**:1-8.

Boogaard, P.J., de Kloe, K.P., Bierau, J., Kuiken, G., Borkulo, P.E., Watson, W.P., and van Sittert, N.J. (2000). Metabolic inactivation of five glycidyl ethers in lung and liver of humans, rats and mice in vitro. *Xenobiotica* **30**:485-502.

Cappaert, N.L., Klis, S.F., Muijser, H., Kulig, B.M., Ravensberg, L.C., and Smoorenburg, G.F. (2002). Differential susceptibility of rats and guinea pigs to the ototoxic effects of ethyl benzene. *Neurotoxicol. Teratol.* **24**:503-10.

Charest-Tardif, G., Tardif, R., and Krishnan, K. (2006). Inhalation pharmacokinetics of ethylbenzene in B6C3F1 mice. *Toxicol. Appl. Pharmacol.* **210**:63-9.

Chin, B.H., McKevley, J.A., Tyler, T.R., Calisti, L.J., Kozbelt, S.J., and Sullivan, L.J. (1980). Absorption, distribution, and excretion of ethylbenzene, ethylcyclohexane, and methylethylbenzene isomers in rats. *Bull. Environ. Contam. Toxicol.* **24**, 477-483.

Dennison, J.E., Bigelow, P.L., Mumtaz, M.M., Andersen, M.E., Dobrev, I.D., and Yang R.S. (2005). Evaluation of potential toxicity from co-exposure to three CNS depressants (toluene, ethylbenzene, and xylene) under resting and working conditions using PBPK modeling. *J. Occup. Environ. Hyg.* **2**:127-35.

Dennison, J.E., Andersen, M.E., and Yang, R.S. (2003). Characterization of the pharmacokinetics of gasoline using PBPK modeling with a complex mixtures chemical lumping approach. *Inhal. Toxicol.* **15**:961-86.

Engstrom, K., Elovaara, E., and Aitio, A. (1985). Metabolism of ethylbenzene in the rat during long-term intermittent inhalation exposure. *Xenobiotica* **15**:281-6.

Engstrom, K., Riihimaki, V., and Laine, A. (1984). Urinary disposition of ethylbenzene and m-xylene in man following separate and combined exposure. *Int. Arch. Occup. Environ. Health.* **54**:355-63.

Faber, W.D., Roberts, L.S., Stump, D.G., Tardif, R., Krishnan, K., Tort, M., Dimond, S., Dutton, D., Moran, E., and Lawrence, W. (2006). Two generation reproduction study of ethylbenzene by inhalation in Crl-CD rats. *Birth Defects Res. B Dev. Reprod. Toxicol.* **77**:10-21.

Freundt, K.J., Römer, K.G., and Federsel, R.J. (1989). Decrease of inhaled toluene, ethyl benzene, m-xylene, or mesitylene in rat blood after combined exposure to ethyl acetate. *Bull. Environ. Contam. Toxicol.* **42**:495-8.

Fuciarelli, A.F. (2000). Ethylbenzene two-week repeated-dose inhalation toxicokinetic study report. NTP Task Number CHEM.2477. Battelle, Richland, Washington. January 2000.

Gentry, P.R., Haber, L.T., McDonald, T.B., Zhao, Q., Covington, T., Nance, P., Clewell, H.J. III, Lipscomb, J.C., and Barton, H.A. (2004). Data for physiologically based pharmacokinetic modeling in neonatal animals: physiological parameters in mice and Sprague-Dawley rats. *J. Child. Health* **2**:363-411.

Gromiec, J.P. and Piotrowski, J.K. (1984). Urinary mandelic acid as an exposure test for ethylbenzene. *Int. Arch. Occup. Environ. Health* **55**:61-72.

Haddad, S., Beliveau, M., Tardif, R., and Krishnan, K. (2001). A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures. *Toxicol. Sci.* **63**:125-31.

Haddad, S., Charest-Tardif, G., Tardif, R., and Krishnan, K. (2000). Validation of a physiological modeling framework for simulating the toxicokinetics of chemicals in mixtures. *Toxicol. Appl. Pharmacol.* **167**:199-209.

Haddad, S., Tardif, R., Charest-Tardif, G., and Krishnan, K. (1999). Physiological modeling of the toxicokinetic interactions in a quaternary mixture of aromatic hydrocarbons. *Toxicol. Appl. Pharmacol.* **161**:249-57.

Heymann, M.A., Iwamoto, H.S., and Rudolph, A.M. (1981). Factors affecting changes in the neonatal systemic circulation. *Ann. Rev. Physiol.* **43**:371-383.

International Commission on Radiological Protection (ICRP) (1975). *Report of the Task Group on Reference Man.* ICRP No. 23. Pergamon Press, Inc. Elmsford, New York.

Jang, J.Y., Droz, P.O., and Kim, S. (2001). Biological monitoring of workers exposed to ethylbenzene and co-exposed to xylene. *Int. Arch. Occup. Environ. Health* **74**:31-7.

Johnsrud, E.K., Koukouritaki, S.B., Divakaran, K., Brunengraber, L.L., Hines, R.N., and McCarver, D.G. (2003). Human hepatic CYP2E1 expression during development. *J. Pharmacol. Exp. Ther.* **307**:402-7.

Kawai, T., Yasugi, T., Mizunuma, K., Horiguchi, S., Iguchi, H., Uchida, Y., Iwami, O., and Ikeda, M. (1992). Comparative evaluation of urinalysis and blood analysis as means of detecting exposure to organic solvents at low concentrations. *Int. Arch. Occup. Environ. Health* **64**:223-34.

Knecht, U., Reske, A., and Woitowitz, H.J. (2000). Biological monitoring of standardized exposure to ethylbenzene: evaluation of a biological tolerance (BAT) value. *Arch. Toxicol.* **73**:632-40.
# Appendix P

Krishnan, K. 2002. Estimation of oral doses for use in a preliminary reproduction study of ethylbenzene in the rat. September 13, 2002. University of Montreal.

Kumarathasan, P., Otson, R., and Chu, I. (1998). Application of an automated HS-GC method in partition coefficient determination for xylenes and ethylbenzene in rat tissues. *Chemosphere* **37**:159-78.

Meulenberg, C.J., Wijnker, A.G., and Vijverberg, H.P. (2003). Relationship between olive oil:air, saline:air, and rat brain:air partition coefficients of organic solvents in vitro. *J. Toxicol. Environ. Health A.* **66**:1985-98.

Nong, A., Charest-Tardif, G., Tardif, R., Lewis, D.F.V., Sweeney, L.M., Gargas, M.L., and Krishnan, K. (2006). Physiologically-based modeling of the inhalation pharmacokinetics of ethylbenzene in B6C3F1 mice. Submitted.

Pierce, C.H., Dills, R.L., Silvey, G.W., and Kalman, D.A. (1996). Partition coefficients between human blood or adipose tissue and air for aromatic solvents. *Scand. J. Work Environ. Health* **22**:112-8.

Romer, K.G., Federsel, R.J., and Freundt, K.J. (1986). Rise of inhaled toluene, ethyl benzene, m-xylene, or mesitylene in rat blood after treatment with ethanol. *Bull. Environ. Contam. Toxicol.* **37**:874-6.

Saghir, S.A. and Rick, D.L. (2005). Ethylbenzene: in vitro metabolism in rat, mouse, and human liver and lung microsomes. The Dow Chemical Company, Midland, Michigan. December 8, 2005.

Sams, C., Loizou, G.D., Cocker, J., and Lennard, M.S. (2004). Metabolism of ethylbenzene by human liver microsomes and recombinant human cytochrome P450s (CYP). *Toxicol. Lett.* **147**:253-60.

Sato, A. and Nakajima, T. (1979). Partition coefficients of some aromatic hydrocarbons and ketones in water, blood and oil. *Br. J. Ind. Med.* **36**:231-4.

Sweeney, L.M. and Gargas, M.L. (2006). PBPK Modeling of Ethylbenzene Exposure of Infants Via Breastmilk. The Sapphire Group, Dayton, Ohio. February 15, 2006. (Appendix N.)

Tardif, R., Charest-Tardif, G., Brodeur J, Krishnan K. (1997). Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans. *Toxicol. Appl. Pharmacol.* **144**:120-34.

Tardif, R., Charest-Tardif, G., and Brodeur, J. (1996). Comparison of the influence of binary mixtures versus a ternary mixture of inhaled aromatic hydrocarbons on their blood kinetics in the rat. *Arch. Toxicol.* **70**:405-13.

U.S. EPA. (2006). Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment (Final Report). U.S. Environmental Protection Agency, Washington, D.C., EPA/600/R-05/043F.

# **APPENDIX Q**

#### **Dose-Response Analyses**

All dose-response modeling for ethylbenzene was performed using U.S. EPA's Benchmark Dose Software (BMDS, version 1.3.2). Details regarding the dose-response modeling efforts conducted using the toxicity data from rats and mice exposed to ethylbenzene are summarized briefly below.

## Q.1 BMDS Output for Ototoxicity (Gagnaire *et al.*, 2006)

The dose associated with a 1.05% loss of OHC3 and its 95% lower confidence limit (LED0105) were considered as the point of departure. The selection of the data set, internal dose metric, and point of departure were discussed above. The resulting ED15dB/LED15dB values are provided in **Table Q-1** and the fit to the dose-response model is shown in **Figure Q-1**.

Model	AIC	<b>P-value</b>	ED0105	LED0105
			(mg/L-hr per week)	(mg/L-hr per week)
Hill	160	0.642	319.6	272.8
Power	213	< 0.0001	24.1	19.2
Polynomial	215	< 0.0001	24.1	19.2
Linear	222	< 0.0001	36.3	29.4

Table O-1.	BMDS	Output for	Gagnaire	et al.	(2006)
- aoit & -		0 40 40 101	Gagnane	<i>ci cii</i> .	(=000)



Figure Q-1. Hill Model Fits to the Dose-Response Data for Ethylbenzene-induced OHC-3 in Rats

## Q.2 BMDS Output for Mouse Liver Effects (NTP, 1999)

The dose associated with a 10 percent increase in liver effects (syncitial alteration) above the background incidence (ED10) and its 95% lower confidence limit (LED10) were considered as the point of departure. The selection of the data set, internal dose metrics, and point of departure were discussed above. The resulting ED10/LED10 values are provided in **Table Q-2** and the fit to the dose-response model is shown in **Figure Q-2**.

Dose Measure	Model	AIC	p-value	EC10	LEC10
AUCL (mg-hr/L per week)	Log-Probit	149.5	0.986	7.5	1.1
(without RPT metabolism)	Log-Logistic	149.5	0.973	7.0	0.9
	Gamma	160.6	0.021	274	188
	Multistage	160.6	0.021	274	188
	Q-linear	160.6	0.021	274	188
	Weibull	160.6	0.021	274	188
	Logistic	161.1	0.018	535	429
	Probit	161.1	0.018	494	395
	Q-quadratic	161.4	0.016	636	526
METL (mg metabolized per	Log-Logistic	152.0	0.289	2211	599.9
kg liver per week)	Log-Probit	152.5	0.234	2049	595.4

 Table Q-2.
 BMDS Output for Mouse Liver Effects in NTP (1999)

Dose Measure	Model	AIC	p-value	EC10	LEC10
	Gamma	154	0.109	4888	3535
	Multistage	154	0.109	4888	3535
	Q-linear	154	0.109	4888	3535
	Weibull	154	0.109	4888	3535
	Probit	156.5	0.105	10327	8480
	Logistic	156.9	0.096	11247	9232
	Q-quadratic	157.9	0.059	11868	9925

**Figure Q-2.** Gamma Model Fits to the Dose-Response Data for Ethylbenzene-induced Liver Effects in Mice



Gamma Multi-Hit Model with 0.95 Confidence Level

(a) AUCL as dose metric





(b) Amount metabolized in liver (METL) as dose metric

## Q.3 BMDS Output for Mouse Pituitary Hyperplasia (NTP, 1999)

The dose associated with a 10 percent increase in pituitary hyperplasia above the background incidence (ED10) and its 95% lower confidence limit (LED10) were considered as the point of departure. The selection of the data set, internal dose metrics, and point of departure were discussed above. The resulting ED10/LED10 values are provided in **Table Q-3** and the fit to the dose-response model is shown in **Figure Q-3**.

Dose Measure	Model	AIC	p-value	EC10	LEC10
AM/BW (mg metabolized per	Gamma	244.4	0.121	900	556
kg body weight per week)	Multistage	244.4	0.121	900	556
	Q-Linear	244.4	0.121	900	556
	Weibull	244.4	0.121	900	556
	Log Probit	244.9	0.099	389	1.45
	Log Logistic	245.1	0.091	340	0.48
	Probit	245.4	0.071	1273	897
	Logistic	245.5	0.068	1310	926
	Q- Quadratic	247.8	0.020	2160	1585

**Table Q-3**. BMDS Output for Mouse Pituitary Hyperplasia in NTP (1999)

**Figure Q-3.** Gamma Model Fits to the Dose-Response Data for Ethylbenzene-induced Pituitary Hyperplasia in Mice





# Q.4 BMDS Output for Rat Liver Effects (Mellert *et al.*, 2004)

The dose associated with a 10 percent increase in liver effects (hypertrophy) above the background incidence (ED10) and its 95% lower confidence limit (LED10) were considered as the point of departure. The selection of the data set, internal dose metrics, and point of departure were discussed above. The resulting ED10/LED10 values are provided in **Table Q-4** and the fit to the dose-response model is shown in **Figure Q-4** 

Dose Measure	Model	AIC	p-value	EC10	LEC10
AUCL (mg/L-hr per week)	Log-Probit	63.0	0.373	51.5	18.0
	Log-Logistic	63.1	0.357	15.2	16.7
	Gamma	63.9	0.106	59.6	40.7
	Multistage	63.9	0.106	59.6	40.7
	Q-linear	63.9	0.106	59.6	40.7
	Weibull	63.9	0.106	59.6	40.7
	Logistic	73.3	0.004	195.8	132.6
	Probit	73.5	0.005	202	148.7
	Q-quadratic	77.4	0.0005	338.9	258.9

Table Q-4. BMDS Output for Rat Liver Effects in Mellert et al. (2004)

Dose Measure	Model	AIC	p-value	EC10	LEC10
AM/VL (mg metabolized/kg	Q-quadratic	61.4	0.576	1841	1546
liver per week)	Logistic	61.7	0.44	2045	1453
	Probit	61.8	0.4523	1887	1354
	Log-Probit	62.3	0.498	2483	1545
	Log-Logistic	62.4	0.483	2511	1514
	Gamma	62.5	0.448	2363	1365
	Weibull	63.1	0.385	2128	1194
	Multistage	63.3	0.389	2013	957
	Q-linear	69.3	0.128	627	456

**Figure Q-4.** Model Fits to the Dose-Response Data for Ethylbenzene-induced Liver Effects in Rat



Gamma Multi-Hit Model with 0.95 Confidence Level

(a) AUCL as dose metric



Quantal Quadratic Model with 0.95 Confidence Level

(b) AM/VL as dose metric

# Q.5 BMDS Output for Effect of Ethylbenzene on Female Rat Mean Corpuscular Volume (Mellert *et al.*, 2004)

The dose associated with a 1-SD increase in the above the control MCV (ED1SD) and its 95% confidence limit (LED1SD) were considered as the point of departure. The selection of the data set, internal dose metrics, and point of departure were discussed above. The resulting ED1SD/LED1SD values are provided in **Table Q-5** and the fit to the dose-response model is shown in **Figure Q-5**.

**Table Q-5**. BMDS Output for Effect on Ethylbenzene on Female Rat Mean Corpuscular

 Volume in Mellert *et al.* (2004)

Dose Measure	Model	AIC	p-value	ED1SD	LED1SD
AUCR	Hill	54.2	NA	144.9	48.8
(mg/L-hr per week)	Linear	54.7	0.032	585.8	414.6
	Polynomial	54.7	0.009	585.8	414.6
	Power	58.7	0.009	585.8	414.6
AM/BW	Linear	50.9	0.212	167.7	122.1
(mg metabolized/kg per	Polynomial	52.9	0.08	179.2	122.3
week)	Hill	54.2	NA	181.6	NC
	Power	54.7	0.091	191.4	123.7

**Figure Q-5.** Model Fits to the Dose-Response Data for Effect on Ethylbenzene on Female Rat Mean Corpuscular Volume



Hill Model with 0.95 Confidence Level

(a) AUCR as dose metric



Linear Model with 0.95 Confidence Level

(b) AM/BW as dose metric

# **Q-6.** BMDS Output for Effect of Ethylbenzene on Female Rat Prothrombin Time (Mellert *et al.*, 2004)

The dose associated with a 1-SD decrease in the below the control prothrombin time (ED1SD) and its 95% confidence limit (LED1SD) were considered as the point of departure. The selection of the data set, internal dose metrics, and point of departure were discussed above. The resulting ED1SD/LED1SD values are provided in **Table Q-6** and the fit to the dose-response model is shown in **Figure Q-6** 

**Table Q-6**. BMDS Output for Effect on Ethylbenzene on Female Rat Prothrombin Time in Mellert *et al.* (2004)

Dose Measure	Model	AIC	p-value	ED1SD	LED1SD
AUCR	Linear	79.5	0.183	841.9	539.3
(mg/L-hr per	Polynomial	79.5	0.065	841.9	539.3
week)	Hill	82.2	NA	176.7	NC
	Power	83.5	0.065	841.9	539.3
AM/BW	Linear	76.8	0.712	235.2	157.8
(mg	Polynomial	76.8	0.409	235.2	157.8
metabolized/kg	Power	80.8	0.409	235.2	157.8
per week)	Hill	82.2	NA	199.1	72.1

Figure Q-6. Model Fits to the Dose-Response Data for Effect on Ethylbenzene on Female Rat Prothrombin



Linear Model with 0.95 Confidence Level







(b) AM/BW as Dose Metric

# Appendix **R**

# PBPK modeling for the interpretation of biomonitoring data on

# ethylbenzene in humans

Kannan Krishnan, Ph.D. (2001)

A written report of the work performed under ACC Agreement No. EB-9.0-CONS-Krishnan

(Minor revisions made for public release under VCCEP by Lisa M. Sweeney, Ph.D., DABT, 2006)

# **1. Description of Report Content**

# 1.1 Overview

The work will facilitate the interpretation of the human biomonitoring data for ethylbenzene (EBZ) based on pharmacokinetic principles. Physiologically-based pharmacokinetic (PBPK) model will be used for interpreting the biomonitoring data (e.g., blood EBZ concentration).

The initial phase involved the reconstruction of the rat and human PBPK models for EBZ (in Microsoft EXCEL) and the successful reproduction of previously published simulations of EBZ kinetics. The PBPK model was used to simulate the kinetics of EBZ in human volunteers exposed to 33 ppm for 7 hr and in rats exposed for 100 or 200 ppm for 4 hr in inhalation chambers (original data published in Toxicology and Applied Pharmacology 144: 120-134, 1997).

# **1.2** Algorithms for EBZ dose reconstruction

The steady-state equations of EBZ kinetics in humans were established and validated by comparing to human PBPK models. These equations, derived from PBPK models, give essentially the same results as the complete PBPK models for repeated exposure situations. These equations require only the blood concentrations as input to provide exposure concentrations as output, i.e., they facilitate dose reconstruction.

## **1.3.** Interpretation of EBZ biomarker data

The deliverables identified in the preceding paras (i.e., PBPK model and steady-state algorithm) can be used for interpreting the blood concentration data collected in human population. Published data on the blood concentrations of EBZ reported in human populations in the literature (probably two studies, to be identified) will be used for the reconstruction of exposure doses at steady-state condition. During this phase, the exposure duration and the exposure scenario that characterize the steady-state condition in normal human populations will be defined.

## 2. Results

# 2.1 Codes for rat and human PBPK models for EBZ

This initial phase involved the reconstruction of the rat and human PBPK models for EBZ (in Microsoft EXCEL) and the successful reproduction of previously published simulations of EBZ kinetics. The PBPK model was used to simulate the kinetics of EBZ in human volunteers exposed to 33 ppm for 7 hr and in rats exposed for 100 or 200 ppm for 4 hr in inhalation chambers (original experimental data published in Toxicology and Applied Pharmacology 144: 120-134, 1997, were retrieved and used in the present study).

The PBPK model used in this study describes the organism as a four compartmental system interconnected by systemic circulation and a gas-exchange lung compartment (Figure 1). The four compartments refer to liver, slowly perfused tissues, richly perfused tissues and adipose tissue (fat). The rate of change in the amount of EBZ in each non-metabolizing tissue compartment is described as follows (Note: all abbreviations are defined in the legend for Figure 2):

$$V_t \frac{dC_t}{dt} = Q_t (C_a - C_{vt}) \tag{1}$$

The rate of change in EBZ concentration in liver is described as follows:

$$V_t \frac{dC_t}{dt} = [Q_t(C_a - C_{vt})] - \frac{dA_{met}}{dt} - \frac{dA_{bm}}{dt}$$
(2)

Rate of change in the amount of the chemical in the tissue = (blood flow x arteriovenous concentration difference) – rate of loss due to metabolism

The rate of the amount metabolized was described as a saturable process as follows:

$$\frac{dA_{met}}{dt} = \frac{V_{max} C_{vt}}{K_m + C_{vt}}$$
(3)

In EBZ PBPK model, the mixed venous blood concentration has been calculated as follows:

$$C_{v} = \frac{\sum_{t}^{n} Q_{t}C_{vt}}{Q_{c}}$$
(4)

The above equation represents the steady-state solution of the mass-balance differential equation for venous blood

$$\left[V_{b}(dC_{b}/dt) = \sum_{t}^{n} Q_{t}C_{vt} - C_{v}Q_{c}\right]$$
(5)

The arterial blood concentration of EBZ is computed with the following equation:

$$C_{a} = \frac{Q_{p}C_{inh} + Q_{c}C_{v}}{Q_{c} + \left(\frac{Q_{p}}{P_{b}}\right)}$$
(6)

The EBZ PBPK model comprises of the above equations, which are interconnected as shown in Figure 2.

In order to simulate the blood and tissue kinetics of EBZ, these mathematical equations should be written in such a way to facilitate their solution by a fixed step-by-step procedure (i.e., algorithm). Using Euler algorithm for integration of differential equations, the PBPK model was written in EXCEL spreadsheets. Accordingly, once (i) the numerical values of model parameters are provided, (ii) the equations in the first and subsequent rows of the spreadsheet are entered, (iii) the time interval for integration is specified, and (iv) the required number of cells are chosen, the simulation begins. One has only to repeat the calculations shown in row 39 of Appendices 1 - 3 for each time interval of integration until the end of the desired duration of simulation. In the present example, the time interval of integration was fixed at 0.005 h. Each line in the Excel spreadsheet then represents calculations characterizing EBZ kinetics at every 0.005 h. Figures 3 and 4 present comparisons of the model predictions with the experimental data on the venous blood concentrations in rats exposed to 100 or 200 ppm of EBZ for 4 hr. Figures 5 and 6 represent the PBPK model predictions of the blood and alveolar air concentrations of EBZ in humans exposed to 33 ppm of this chemical for seven hours under controlled conditions (Experimental data from Tardif et al. 1997. Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans. Toxicology and Applied Pharmacology. 144: 120-134). A complete set of the simulation results for 100 ppm rat exposure, 200 ppm rat exposure and 33 ppm human exposure are included in Appendices 1, 2 and 3. Note that all physiological and physicochemical parameters used in the present study correspond to those of Tardif et al. (1997). The biochemical constants however are from Haddad et al. (2000) who refined the estimates of Tardif et al (1997). All parameter values are provided in Tables 1 and 2.

#### 2.2. Algorithms for EBZ dose reconstruction

Algebraic expressions for calculating the steady-state concentrations of EBZ in certain biological fluids (arterial blood, venous blood, alveolar air) were established per Pelekis et al. (1997) (Toxicology Methods 7: 205-225). The steady-state concentrations obtained with these equations were compared with the simulations of full-fledged human PBPK model for EBZ. These equations, following validation, were written in such a form that it will require only the biomarker concentrations as input to provide exposure concentrations as output, i.e., facilitate dose reconstruction.

By combining Eqn. 6 with Eqn. 4, the following steady-state equation was established:

$$Cass = \underline{R x Ci}.$$

$$(R/Pb) + (QLC x E)$$
(7)

where Cass = steady-state arterial blood concentration (mg/L), R = ratio of Qp/Qc, i.e., ratio of alveolar ventilation rate to the cardiac output, Ci = inhaled or exposure concentration, Pb = blood:air partition coefficient, QLC = fraction of cardiac output flowing through liver, and E = hepatic extraction coefficient. Since the Qp and Qc values

are equivalent in the PBPK models used in the present study, the R value was set to 1. Therefore, the above equation becomes,

$$Cass = \underline{Ci} \\ (1/Pb) + (QLC \times E)$$
(8)

The numerical values of the following parameters are required for establishing the relationship between blood concentration (Cass) and inhaled concentration (Ci) of EBZ, at steady-state: (1) Pb, (2) QLC, and (3) E.

The average human Pb is 28 (Tardif et al. 1997). The average QLC value is 0.26 (Tardif et al. 1997). The E for ethyl benzene was calculated as follows:

$$E = \frac{CLint}{CLint + QL}$$
(9)

where CLint = intrinsic clearance calculated as Vmax divided by Km for first order conditions, and QL = liver blood rate in humans. QL was set equal to 113.3 L/hr (Tardif et al., 1997). CLint was calculated using Vmax value for a 70 kg human (6.39 x body weight<sup>0.75</sup>) and Km value (1.042 mg/L) reported by Haddad et al. (2000). The CLint obtained in this manner was 148.3 L/hr. The E for EBZ was then calculated as follows:

$$E = \frac{148.3}{148.3 + 113.3}$$
(10),

which is equal to 0.567. This value of hepatic extraction ratio was also computed using human PBPK model for EBZ and was found to be 0.567071. The PBPK computation was based on the arterial blood concentration and hepatic venous blood concentrations associated with a 1 ppm inhalation exposure to EBZ.

Using the average values of Pb (28), QLC (0.26) and E (0.567) for EBZ, the steady-state arterial blood concentration can be calculated as follows:

$$Cass = \underline{Ci} (1/Pb) + (QLC \times E)$$
(8)

Cass = 
$$\underline{Ci}$$
  
(1/28) + (0.26 x 0.567) (11)

Alternativevly,

$$Ci = Cass [(1/28) + (0.26 \times 0.567)]$$
(12)

Simplifying the above equation, we get:

 $Ci = Cass \ge 0.1831$  (13)

Using the above equation, the inhalation or exposure concentration of EBZ can be backcalculated with information on the steady-state blood concentration.

For validating the above relationship, the calculated Cass value was compared with that simulated by a full-fledged human PBPK model, for a 1 ppm EBZ inhalation exposure. With the above Eqn, the Cass associated with 1 ppm or 0.004335 mg/L EBZ exposure will be equal to:

Cass =  $\frac{0.004335}{0.1831}$  which equals 0.02368 mg/L.

The Cass simulated by the validated human PBPK model, for a continuous inhalation exposure to 1 ppm, was 0.0233 mg/L.

The above two values compare well and are within about 2% of each other. The small difference is likely to be due to the rounding off differences between the computer program vs manual calculations.

Table 3 presents the relationship between exposure concentration and steady-state blood concentrations of EBZ. The arterial and venous blood concentrations at steady-state are related by the following equation:

 $Cass (1 - QLC \times E) = Cv$ (14)

In Table 3, the Cass values associated with any exposure level can be multiplied with 0.8526 to obtain the venous blood concentrations. The value of 0.8526 was derived as (1-QLC x E) or  $(1 - 0.26 \times 0.567)$ , and this is valid only for low exposure concentrations (i.e., those that give blood concentrations that are very low compared to the Km value). This is likely to be true for upto 10 ppm EBZ.

The back-calculation algorithm relating the exposure concentration to the venous blood concentration then is as follows:

$$Ci = \frac{Cv (1/Pb + QLC \times E)}{(1 - QLC \times E)}$$
(15)

The steady-state alveolar concentrations are related to the arterial blood concentration by the blood:air partition coefficient. The back-calculation algorithm, based on Eqn. 8, is as follows:

$$Ci = Calv (1 + QLC x E x Pb)$$
(16)

In summary, the back-calculation algorithms established in the present study for EBZ are listed in the following table:

Input parameter	Algebraic equation	Simplified form
Arterial blood conc. (Ca)	$Ca (1/Pb + QLC \times E)$	Ca x 0.1831
Venous blood conc. (Cv)	$Cv (1/Pb+QLC \times E)$	Cv x 0.2148
	(1 - QLC x E)	
Alveolar air conc. (Calv)	Calv (!+ QLC x E x Pb)	Calv x 5.13

 Table 4. Back-calculation algorithms for EBZ.

The equations in columns 2 and 3 above give exposure concentrations or inhaled concentrations as output. The simplified forms presented in Column 3 were derived using the numerical values of parameters for an average individual (Pb = 28, QLC = 0.26, E = 0.567), as specified in the PBPK models of Tardif et al. (1997) and Haddad et al. (2000). The above equations provide the same results of back-calculations as full-fledged PBPK models, for steady-state conditions.

## **2.3. Interpretation of EBZ biomarker data**

The results from sections 2.1 and 2.2 (i.e., PBPK model and steady-state algorithms) can be used for interpreting the blood concentration data collected in human population. For steady-state conditions or repeated exposures during lifetime (which are typically considered in risk assessment practices), the algebraic equations developed in this study provide results that are identical to that of the validated human PBPK model for EBZ. Therefore, the steady-state algorithms in their simplified form were used in this phase for dose reconstruction purposes. Published data on the blood concentrations of EBZ reported in human populations in the literature were used for the reconstruction of exposure concentrations at steady-state condition. The human studies useful for this purpose were identified following considerable review and careful examination of the relevant literature in the area of biomonitoring of volatile organic chemicals. The following studies were reviewed:

Ashley DL,Bonin MA, Cardinali FL, McCraw JM and Wooten JV. Blood concentrations of volatile organic compounds in a nonoccpationally exposed US population and in groups with suspected exposure. Clinical Chemistry 40(7) (1994) 1401-1404.

Ashley DL, Bonin MA, Cardinali FL, McCraw JM and Wooten JV. Measurement of volatile organic compounds in human blood. Environmental Health Perspectives 104, Suppl 5 (1996) 871-877.

Ashley DL and Prah JD. Time dependence of blood concentrations during and after exposure to a misture of volatile organic compounds. Archives of Environmental Health 52 (11) (1997) 26-33

Heinrich-Ramm R, Jakubowski M, Heinzow B, Molin Christensen J, Olsen E and Hertel O. Biological monitoring for exposure to volatile organic compounds (VOCs). Pure and Applied Chemistry 72 (3) (2000) 385-436.

Mannino DM, Schreiber J, Aldous K, Ashley D, Moolenaar R and Almaguer D. Human exposure to volatile organic compounds : a comparison of organic vapor monitoring badge levels with blood levels. International Archives in Occupational Environmental Health 67 (1995) 59-64.

Needham LL, Hill RH, Ashley Jr DL, Pirkle JL and Sampson EJ. The priority toxicant reference range study interim report. Environmental Health Perspectives 103, Suppl 3 (1995) 89-94.

Raymer JH, Pellizzari ED, Thomas KW, Kizakevich P and Cooper SD. Kinetics of lowlevel volatile organic compounds in breath-II: relationship between concentrations measured in exposure air and alveolar air. Journal of Exposure Analysis and Environmental Epidemiology 2 (2) (1992) 67-83.

Romieu I, Ramirez M, Meneses F, Ashley D, Lemire S, Colome S, Fung K and Hernandez-Avila M.Environmental Health Perspectives 107 (7) (1999) 511-515. Environmental exposure to volatile organic compounds among workers in Mexico City as assessment by personnal monitors and blood concentrations. Environmental Health Perspectives 107 (7) (1999) 511-515.

Tang W , Hemm I and Eisenbrand G. Estimation of human exposure to styrene and ethylbenzene. Toxicology 144 (2000) 39-50.

Wallace L, Pellizzari E,Hartwell, TD, Perritt R and RZiegenfus R. Exposures to benzene and other volatile compounds from active and passive smoking. Archives of Environmental Health 42 (5) (1987) 272-279.

Wallace L, Nelson W, Ziegenfus R, Pellizzari E, Michael L, Whiymore R, Zelon H, Hartwell T, Perritt R and Westerdahl D. The Los Angeles team study :personal exposures, indoor-outdoor air concentrations of 25 volatile organic compounds. Journal of Exposure Analysis and Environmental Epidemiology 1 (2) (1991) 157-192.

Wallace LA and Pellizzari ED. Recent advances in Measuring exhaled breath and estimating exposure and body burden for volatile organic compounds. (VOCs). Environmental Health Perspectives 103 (3) (1995) 95-98.

Wallace L, Buckley T, Pellizzari E and Gordon S. Breath measurements as volatile organic compound biomarkers. Environmental Health Perspectives 104 (5) (1996) 861-869.

Wallace L, Pellizzari E and Gordon S. A linear model relating breath concentrations to environmental exposures : application to a chamber study of four volunteers exposed to volatile organic chemicals. Journal of Exposure Analysis and Environmental Epidemiology 3 (1) (1993) 75-102.

Yang JY, Droz PO and Kim S. Biological monitoring of workers exposed to ethylbenzene and co-exposed to xylene. International Archives in Occupational Health 74 (2001) 31-37.

# Example 1

The back-calculations were initially done using blood concentration data reported by Mannino et al. (1995). These authors reported the median EBZ blood concentration to be 0.23  $\mu$ g/L in people exposed to gasoline fumes and automobile exhaust in Albany, NY. (They also reported that the median exposure concentration was 54  $\mu$ g/m<sup>3</sup>, which was determined using vapor badges).

According to the steady-state equations developed in the present study and validated using the human PBPK model for EBZ, the exposure concentration of EBZ can be predicted or back-calculated as follows:

 $Ci (\mu g/L) = Ca (\mu g/L) \times (1/Pb + QLC \times E)$ 

or simply,

Ci ( $\mu$ g/L) = Ca ( $\mu$ g/L) x 0.1831

For the Cass of 0.23  $\mu$ g/L reported by Mannino et al. (1985), the back-calculated Ci is 0.042  $\mu$ g/L or 42  $\mu$ g/m<sup>3</sup>. The actual, median exposure concentration determined using vapor badges was 54  $\mu$ g/m<sup>3</sup>. Even though the back-calculation was performed using the parameter values for an average individual, the predicted exposure concentration compares reasonably well with the field measurement data (42 vs 54 as median values). The same result is obtained using the simulations of human PBPK model for EBZ. In this case, a graph between the simulated steady-state blood concentration and exposure concentration is established, and then one can be calculated by knowing the other. The relationships established using EBZ PBPK model in this study are plotted in Figures 7 and 8.

# Example 2

Another set of back-calculations were done using, not just the median value but using the minimum and maximum values reported by Mannino et al. (1995). These authors reported EBZ concentrations varying from 0.04 to 3.03  $\mu$ g/L in individuals exposed to gasoline fumes and automobile exhaust in Albany, NY. (The authors also reported that the atmospheric concentrations varied from the limit of detection (8  $\mu$ g/m<sup>3</sup>) to 780  $\mu$ g/m<sup>3</sup>, which was determined using vapor badges).

According to the steady-state equations developed in the present study and validated using human PBPK model for EBZ, the exposure concentration of EBZ can be predicted or back-calculated as follows:

Ci  $(\mu g/L) = Ca (\mu g/L) \times (1/Pb + QLC \times E)$ 

or simply,

Ci  $(\mu g/L) = Ca (\mu g/L) \ge 0.1831$ 

For the lowest Cass of 0.04  $\mu$ g/L reported by Mannino et al. (1985), the back-calculated Ci obtained in the present study is 0.00732  $\mu$ g/L or 7.32  $\mu$ g/m<sup>3</sup>. The authors' reported lowest exposure concentration corresponding to the limit of detection of the method used was in fact 8  $\mu$ g/m<sup>3</sup>. For the highest Cass of 3.03  $\mu$ g/L reported by Mannino et al. (1985), the back-calculated Ci obtained in the present study is 0.5548  $\mu$ g/L or 554.8  $\mu$ g/m<sup>3</sup>. The authors' reported highest exposure concentration was 780  $\mu$ g/m<sup>3</sup> as determined by vapor badges. Even though the back-calculation was performed using the parameter values for an average individual, the predicted exposure concentration is reasonably close to the field measurement data (555 vs 780 as maximal values).

## Example 3

Ashley et al. (1994) reported the blood concentrations of EBZ in nonoccupationally exposed US population and in groups of people suspected of exposure, as a part of NHANES III. Their survey indicated that the mean, median, 5<sup>th</sup> percentile and 95<sup>th</sup> percentile values of EBZ blood concentration in a group of 631 people were 0.11 ppb, 0.06 ppb, 0.02 ppb (LOD of method) and 0.25 ppb, respectively. These values can be interpreted in terms of exposure concentrations of EBZ, on the basis of pharmacokinetic principles and steady-state algorithms established in this study. Accordingly,

Ci, mean =  $0.11 \ \mu g/L \ x$   $0.1831 = 0.020 \ \mu g/L \ or 20 \ \mu g/m^3$ Ci, median =  $0.06 \ \mu g/L \ x \ 0.1831 = 0.011 \ \mu g/L \ or 11 \ \mu g/m^3$ Ci, 5<sup>th</sup> percentile =  $0.02 \ \mu g/L \ x \ 0.1831 = 0.0037 \ \mu g/L \ or 3.7 \ \mu g/m^3$ Ci, 95<sup>th</sup> percentile =  $0.25 \ \mu g/L \ x \ 0.1831 = 0.04578 \ \mu g/L \ or 46 \ \mu g/m^3$ 

These back-calculated exposure concentrations of EBZ are well within the reported outdoor and indoor concentrations in US reported by Wallace and co-workers.

## Example 4

Another study that reported blood concentrations without any interpretations (relating back to exposure concentrations) is that of Needham and co-workers of CDC in 1995. Based on a survey of about 600 samples, these authors reported the following data for EBZ:

Median:	50 ppt or 0.05 ppb or 0.05 $\mu$ g/L
Mean:	100 ppt or 0.1 ppb or 0.1 µg/L
95%UCL:	300 ppt or 0.3 ppb or 0.3 µg/L

The following are the back-calculations of Ci from the above blood concentration data:

Ci, median =  $0.05 \ \mu g/L \ x \ 0.1831 = 0.009155 \ \mu g/L \ or \ 9.2 \ \mu g/m^3$ Ci, mean =  $0.1 \ \mu g/L \ x \ 0.1831 = 0.01831 \ \mu g/L$  or  $18 \ \mu g/m^3$ Ci, 95% UCL =  $0.3 \ \mu g/L \ x \ 0.1831 = 0.05493 \ \mu g/L$  or  $55 \ \mu g/m^3$ 

These back-calculated values compare well with those obtained for the study of Ashley et al. reported above. The back-calculated EBZ values are all within the exposure concentrations (outdoor, indoor, personal) reported by Wallace et al. (1991) of the US EPA, based on the results of a TEAM study.

#### Additional work relating to breath concentrations of EBZ

Two types of data are produced from biomonitoring studies in which breath concentrations are measured. The first one relates to the calculation of the ratio of breath concentration to ambient air concentration, whereas the other one relates to the reporting of the raw numbers of alveolar air concentrations.

Since

$$Ci = Calv (1 + QLC x E x Pb)$$
(16)

$$\frac{Ci}{Calv} = \frac{1}{1+QLC \times E \times Pb}$$
(17)

Accordingly, in the typical individual considered in the present study, the Ci/Calv is equal to 0.195. The corresponding value derived by Wallace et al. based on a population study is  $0.10 \pm 0.03$ .

The average breath concentration of EBZ determined in 322 non-smokers varied from 0.3 to 2  $\mu$ g/m<sup>3</sup> in various populations. Using these data, the back-calculated exposure concentrations were 1.54 to 10.26  $\mu$ g/m<sup>3</sup> whereas the field measurements indicate 2.1 to 8  $\mu$ g/m<sup>3</sup>.

The appropriateness of the use of the developed algorithms depends on the existence of steadystate condition. The time constant which is useful in determining the taken to the attainment of steadystate was calculated for all PBPK model compartments. The time constants indicate the time taken to attain 50% of the steadystate concentration. And these values are determined by the magnitude of the tissue:blood partition coefficients, tissue volumes and tissue blood flow rates in addition to the intrinsic clearance in the metabolizing tissues. The time constants of EBZ in adipose tissue, slowly perfused tissues, richly perfused tissues and liver correspond to 33.9 hr, 0.21 hr, 0.08 hr and 0.02

hr, respectively. The Figures 9 - 13 indicate the attainment of steadystate as a function of EBZ exposure time. These results suggest that exposure durations of about 100 hr would well approximate steady-state in all compartments. Any exposure duration greater than 4 hr is likely to generate blood concentration data comparable to steady-state values expressed with error ranges or individual variabilities.

# 3. Conclusions

The results of this study are: (1) steady-state algorithms for back-calculating exposure concentrations from biomarker data for EBZ, and (2) sample interpretations of EBZ biomarker data based on pharmacokinetic principles. The results of (1) are presented in the form of simple equations in Table 4. Few examples of back-calculations of exposure concentrations from blood and breath concentrations are provided in Section 2.3. The ground-work performed in the present study should facilitate more sophisticated back-calculations and interpretations of EBZ biomarker data, not only in individuals but also in populations (using probability distributions of parameter values) and specific sub-populations (e.g., children). Further studies are also essential to establish the reference concentration of EBZ in terms of biomarker concentrations in humans.

# FIGURE LEGENDS

Figure 1. Conceptual representation of the PBPK model for EBZ.

Figure 2. Conceptual and fundamental representations of the PBPK model for EBZ. Cinh and Calv refer to inhaled and exhaled EBZ concentrations. Cv and Ca refer to venous and arterial blood concentrations. Pb refers to blood:air partition coefficient. Qp and Qc refer to alveolar ventilation and cardiac output. Cv*i*, Vi, Pi, Ai and Q*i* refer to venous blood concentrations leaving tissue compartments, tissue volumes, tissue:blood partition coefficients, amount in tissues and blood flow to tissues (i.e., f: adipose tissue, s: slowly perfused tissues, r: richly perfused tissues, and l: liver). Vmax, Km and Amet refer to the maximal velocity of metabolism, Michaëlis affinity constant, and amount metabolized. dt refers to integration interaval.

Figure 3. Comparison of PBPK model simulations of venous blood concentrations of ethylbenzene with experimental data (symbols) obtained in rats exposed for 4 hr to 100 ppm of this solvent.

Figure 4. Comparison of PBPK model simulations of venous blood concentrations of ethylbenzene with experimental data (symbols) obtained in rats exposed for 4 hr to 200 ppm of this solvent.

Figure 5. Comparison of PBPK model simulations of venous blood concentrations of ethylbenzene with experimental data (symbols) obtained in human volunteers exposed for 7 hr to 33 ppm of this solvent.

Figure 6. Comparison of PBPK model simulations of alveolar air concentrations of ethylbenzene with experimental data (symbols) obtained in humans exposed for 7 hr to 33 ppm of this solvent.

Figure 7. Relationship between exposure concentration of EBZ (0.0001 - 50 ppm) and PBPK model simulations of venous blood concentrations at steady-state.

Figure 8. Relationship between exposure concentration of EBZ (0.0001 - 1 ppm) and PBPK model simulations of venous blood concentrations at steady-state.

Figure 9. PBPK model simulation of the time-course of the fraction of steady-state adipose tissue concentration attained during continuous exposure of humans to 1 ppm EBZ.

Figure 10. PBPK model simulation of the time-course of the fraction of steady-state liver concentration attained during continuous exposure of humans to 1 ppm EBZ.

Figure 11. PBPK model simulation of the time-course of the fraction of steady-state slowly perfused tissue concentration attained during continuous exposure of humans to 1 ppm EBZ.

Figure 12. PBPK model simulation of the time-course of the fraction of steady-state richly perfused tissue concentration attained during continuous exposure of humans to 1 ppm EBZ.

Figure 13. PBPK model simulation of the time-course of the fraction of steady-state blood concentration attained during continuous exposure of humans to 1 ppm EBZ.


























Parameters	Values
Alveolar ventilation rate (liters/hr/kg)	15.0
Cardiac output (liters/hr/kg)	15.0
Fraction of cardiac output corresponding to each compartment	
Fat	0.09
Slowly perfused tissues	0.15
Richly perfused tissues	0.51
Liver	0.25
Fraction of body weight corresponding to each compartment	
Fat	0.09
Slowly perfused tissues	0.72
Richly perfused tissues	0.05
Liver	0.049
Blood:air	42.7
Fat:air	1556.0
Slowly perfused tissues:air	26.0
Richly perfused tissues:air	60.3
Liver:air	83.8
Metabolic constants	
$V_{max}(mg/hr/kg)$	6.39 <sup>f</sup>
K <sub>m</sub> (mg/liter)	1.04

Table 1.	Parameters	used in	the rat	EBZ	PBPK	Model
14010 11	I analle corb		une nat			

Parameters	Values
Alveolar ventilation rate (liters/hr/kg)	18.0
Cardiac output (liters/hr/kg)	18.0
Fraction of cardiac output corresponding to each compartment	
Fat	0.05
Slowly perfused tissues	0.25
Richly perfused tissues	0.44
Liver	0.26
Fraction of body weight corresponding to each compartment	
Fat	0.19
Slowly perfused tissues	0.62
Richly perfused tissues	0.05
Liver	0.026
Blood:air	28.0
Fat:air	1556.0
Slowly perfused tissues:air	26.0
Richly perfused tissues:air	60.3
Liver:air	83.8
Metabolic constants	
V <sub>max</sub> (mg/hr/kg)	6.39
K <sub>m</sub> (mg/liter)	1.04

Table 2. Parameters used in the human PBPK Model for EBZ.

Exposure con	ncentration	Arterial blood conc (mg/L)	Venous blood conc. (mg/L)					
Ppm	mg/L		_					
0.0001	4.34E-07	2.32E-06	1.97E-06					
0.001	4.34E-06	2.32E-05	1.97E-05					
0.01	4.343-05	2.32E-04	1.97E-04					
0.1	4.34E-04	0.00232	1.97E-03					
1	4.34E-03	0.0233	0.0198					
5	2.17E-02	0.118	0.1004					
10	4.34E-02	0.24	0.2052					
15	6.50E-02	0.367	0.315					
20	8.67E-02	0.499	0.43					
25	1.08E-01	0.637	0.55					
30	1.30E-01	0.782	0.68					
35	1.52E-01	0.935	0.82					
40	1.73E-01	1.1	0.962					
45	1.95E-01	1.27	1.12					
50	2.17E-01	1.44	1.28					

Table 3. Steady-state arterial and venous blood concentrations associated with EBZ exposures (0.0001 ppm to 50 ppm).

Table 4. Back-calculation algorithms for EBZ.

Input parameter	Algebraic equation	Simplified form
Arterial blood conc. (Ca)	$Ca (1/Pb + QLC \times E)$	Ca x 0.1831
Venous blood conc. (Cv)	$Cv (1/Pb+QLC \times E)$	Cv x 0.2148
	(1 - QLC x E)	
Alveolar air conc. (Calv)	Calv (!+ QLC x E x Pb)	Calv x 5.13

Note: The equations in columns 2 and 3 above give exposure concentrations or inhaled concentrations as output. The simplified forms presented in Column 3 were derived using the numerical values of parameters for an average individual (Pb = 28, QLC = 0.26, E = 0.567), as specified in the PBPK models of Tardif et al. (1997) and Haddad et al. (2000). The above equations provide the same results of back-calculations as full-fledged PBPK models, for steady-state conditions.

### Appendix S

### Comparative *In Vitro* Metabolism of Ethylbenzene in Mouse, Rat and Human Liver and Lung Microsomes: Study Summary and Implications for the Ethylbenzene VCCEP Assessment

#### S.1 Study Summary

The mode of action for mouse-specific lung toxicity and carcinogenicity of ethylbenzene is hypothesized to be mediated through preferential mouse lung metabolism to cytotoxic ring-oxidized metabolites. Consistent with this hypothesis, preliminary *in vitro* studies confirmed ethylbenzene was extensively metabolized by mouse lung microsomes, and was approximately 2X greater than rat and significantly greater than human (Saghir et.al., 2006). Although these data indicated lung alkyl-oxidation of ethylbenzene primarily to 1-phenylethanol and acetophenone, very little aromatic-oxidation to either 2- or 4ethylphenol was detected. However, the limited detection of aromatic oxidation was attributed to limitations in the experimental approach used in the preliminary study, in that the preliminary study employed analytical methods likely to identify only monohydroxylated aromatic metabolites. If such metabolites were rapidly oxidized to dihydroxylated catechol and quinone metabolite(s), they likely would not have been detected since these metabolites would also be expected to undergo further oxidation to tissue reactive quinone metabolites. Trapping by nucleophiles such as reduced glutathione (GSH) would be necessary to assure detection and quantitation of quinone metabolites. The possibility that such additional ring oxidative metabolism was indeed likely was supported by the observation that mouse lung microsomes were capable of rapidly metabolizing both 2- and 4-ethylphenol (as measured by disappearance of these substrates).

A follow-up set of comparative *in vitro* mouse, rat and human metabolism studies were conducted to further examine and quantify potential formation of di-hydroxylated ring-oxidized metabolites, using GSH to specifically trap quinone metabolites of catechol and/or hydroquinone (The Dow Chemical Company, 2005). In addition, this protocol was designed to evaluate the comparative rates of metabolism of ethylbenzene to both alkyl- and ring-oxidized metabolites in order to provide data for future refinements to a published ethylbenzene PBPK model.

The results of the Phase II mouse, rat and human liver and lung comparative metabolism experiments (The Dow Chemical Company, 2006) are summarized in Tables S-1 to S-4. These studies confirmed that ethylbenzene, over a range of *in vitro* concentrations of 0.22-7.0 mM, was metabolized to the alkyl-metabolites 1-phenylethanol and acetophenone in liver microsomes from all species (mouse > rat ~ human). At the lower incubation concentrations examined alkyl-oxidation was greater in mouse lung microsomes relative to both mouse liver and rat lung and liver, suggesting that lung metabolism may be a significant contributor to the overall *in vivo* metabolism of ethylbenzene in mice. Although significant alkyl-oxidation was observed in human liver, it was not detected in human lung microsomes. An examination of the mass balance of

alkyl-metabolite generation indicated this route of metabolism represented the major pathway of overall ethylbenzene oxidation in that such metabolites accounted for the majority of the ethylbenzene lost in the microsomal incubations.

Use of GSH-trapping to detect catechol and hydroquinone metabolites (Figure S-1) confirmed the *in vitro* formation of these metabolites in mouse, rat and human liver microsomes, and in mouse and rat, but not human, lung microsomes. Similar to the generation of alkyl-oxidized metabolites, mouse lung microsomes exhibited the substantially higher metabolic activity (mouse lung GSH-derived metabolites approximately 10X > rat lung; human lung not detectable; mouse lung GSH metabolites approximately 2X > mouse liver; mouse liver approximately 10X > rat and human liver). Although ring-oxidized metabolites accounted for a relatively small fraction of overall ethylbenzene metabolism, its selective elevation in mouse lung microsomes is nonetheless consistent with the hypothesized mode of action attributing preferential formation of lung-derived cytotoxic, ring-oxidized metabolites as driving the mouse lung specific toxicity of ethylbenzene. Interestingly, both mouse and rat lung microsomes exhibited decreasing amounts of ring-oxidized metabolite formation with increasing concentrations of ethylbenzene, suggesting the possibility of cytochrome P450 suicide inhibition by reactive ring-oxidized metabolite(s). This observation would also be consistent with the hypothesis of the preferential formation of reactive cytotoxic metabolites in mouse lung.

## S.2 Implications for Ethylbenzene VCCEP Risk Assessment

A complete, final report on the foregoing experiments was not available at the time of the preparation of this VCCEP assessment (The Dow Chemical Company, 2006), and thus could not be incorporated into the toxicity value derivation and risk assessment (Sections 8 and 9). However, sufficient preliminary data are available to further evaluate an important estimate used in the toxicity reference value derivation—the maximal rate of pulmonary ethylbenzene metabolism in the mouse (Tables 8-9 and P-6).

## Impact on Lung Cancer Toxicity Reference Value

In developing a toxicity reference value based on male mouse lung cancer (Section 8), a mouse PBPK model with a pulmonary Vmax of 4.65 mg/hr/kg<sup>0.75</sup> (derived from the *in vitro* data of Saghir and Rick, 2005) was used. Based on the production of 1-phenylethanol and acetophenone during incubations of mouse lung microsomes with 7 mM ethylbenzene (Table S-4), a preliminary, revised pulmonary Vmax estimate of 10.4 mg/hr/kg<sup>0.75</sup> is obtained, using the scaling procedures previously described in Appendix P. This preliminary revised value is >2X higher than the previous estimate of pulmonary metabolism, indicating greater metabolism in mouse lung than was used to derive the lung cancer toxicity reference value. However, the simulated amount of lung metabolism at 75 ppm, the low dose in the cancer bioassay, was also highly dependent on the Michaelis constant (KM) for lung metabolism (Table P-6), which was derived through optimization of fit to blood ethylbenzene concentrations for mice exposed to 75, 200, 500, and 1000 ppm ethylbenzene (Charest-Tardiff *et al.*, 2006). If the lung metabolism

KM is not substantially increased in optimization, the toxicity reference value for lung cancer is likely to increase; if it increases in parallel with the increase in Vmax, the lung cancer toxicity reference value would be expected to be unchanged.

### Impact on Toxicity Reference Values for Liver-Related Endpoints

The dose metric used to derive toxicity reference values based on mouse liver effects is altered by changing the rate of pulmonary metabolism in isolation from other parameter changes (Table P-6). However, when estimate of the rate of metabolism in richly perfused is adjusted as well, in order to fit observed blood ethylbenzene concentrations (Charest-Tardif *et al.*, 2006), the compensatory adjustment results in predictions of liver metabolism that are virtually unchanged (Table 8-9). Thus a change in the estimated rate of pulmonary metabolism of ethylbenzene in mice is unlikely to have a significant impact on internal dosimetry estimates for non-pulmonary tissues.

#### Impact on Risk Characterization

Based on review of these preliminary data, consideration of the final report (if unchanged) would be likely to leave the toxicity reference values unaltered or increased. The key toxicity reference values, those related to mouse liver toxicity (noncancer and cancer), are likely to be unaltered. Thus the risk estimates provided in Section 9 would be likely to be unaltered based on a full consideration of the final data.

#### S.3 References

- Charest-Tardif G., Tardif, R., and Krishnan, K. (2006). Inhalation pharmacokinetics of ethylbenzene in B6C3F1 mice. *Toxicol. Appl. Pharmacol.* **210**:63-69.
- Saghir, S.A. and Rick, D.L. (2005). Ethylbenzene: in vitro metabolism in rat, mouse, and human liver and lung microsomes. The Dow Chemical Company, Midland, Michigan. December 8, 2005.
- Saghir, S.A., Rick, D.L., Bartels, M.J., and Bus, J.S. (2006). *In vitro* metabolism of ethylbenzene by rat, mouse and human liver and lung microsomes. The Toxicologist. 90:141.
- The Dow Chemical Company (2005). Protocol: Ethylbenzene: In Vitro Metabolism With Rat, Mouse And Human Liver And Lung Microsomes Phase II Study. Study ID 051189.
- The Dow Chemical Company (2006). Personal communication from James S. Bus to Lisa Sweeney and Michael Gargas. December 4, 2006.

	Mouse	Liver Incu	ubations	Rat Li	ver Incub	ations	Human Liver Incubations			
Treatment	EB	1-PE	AcPh	EB	1-PE	AcPh	EB	1-PE	AcPh	
	(ug/mL)	(ug/mL)	(ug/mL)	(ug/mL)	(ug/mL)	(ug/mL)	(ug/mL)	(ug/mL)	(ug/mL)	
Control no	57.2 <sup>a</sup>	<llq td="" °<=""><td><llq <sup="">d</llq></td><td></td><td></td><td></td><td></td><td></td><td></td></llq>	<llq <sup="">d</llq>							
microsomes										
Control no	<llq <sup="">b</llq>	<llq td="" °<=""><td><llq <sup="">d</llq></td><td><llq <sup="">b</llq></td><td><llq <sup="">c</llq></td><td><llq<sup>d</llq<sup></td><td><llq<sup>b</llq<sup></td><td><llq <sup="">c</llq></td><td>0.452</td></llq>	<llq <sup="">d</llq>	<llq <sup="">b</llq>	<llq <sup="">c</llq>	<llq<sup>d</llq<sup>	<llq<sup>b</llq<sup>	<llq <sup="">c</llq>	0.452	
substrate										
0.45 no NADPH	44.8	<llq td="" °<=""><td><llq<sup>d</llq<sup></td><td>46.4</td><td><llq td="" °<=""><td><llq<sup>d</llq<sup></td><td>44.9</td><td><llq td="" °<=""><td><llq<sup>d</llq<sup></td></llq></td></llq></td></llq>	<llq<sup>d</llq<sup>	46.4	<llq td="" °<=""><td><llq<sup>d</llq<sup></td><td>44.9</td><td><llq td="" °<=""><td><llq<sup>d</llq<sup></td></llq></td></llq>	<llq<sup>d</llq<sup>	44.9	<llq td="" °<=""><td><llq<sup>d</llq<sup></td></llq>	<llq<sup>d</llq<sup>	
1.8 no NADPH	182	<llq <sup="">c</llq>	<llq<sup>d</llq<sup>	202	<llq <sup="">c</llq>	<llq <sup="">a</llq>	202	<llq td="" °<=""><td><llq<sup>d</llq<sup></td></llq>	<llq<sup>d</llq<sup>	
7 no NADPH	737	<llq <sup="">c</llq>	<llq <sup="">d</llq>	789	<llq <sup="">c</llq>	<llq <sup="">d</llq>	783	<llq td="" °<=""><td><llq <sup="">d</llq></td></llq>	<llq <sup="">d</llq>	
0.22a	5.93	10.2	1.42	32.1	5.33	0.664	19.6	5.93	<llq<sup>d</llq<sup>	
0.22b	10.3	8.88	1.57	24.8	3.46	0.406	18.2	3.71	<llq <sup="">d</llq>	
0.22c	16.4	8.23	1.43	22.7	3.24	0.407	20.6	4.19	<llq <sup="">d</llq>	
Average:	10.9	9.10	1.47	26.5	4.01	0.492	19.5	4.61	<llq <sup="">d</llq>	
%RSD:	48.3%	11.0%	5.69%	18.6%	28.6%	30.20%	6.19%	25.3%		
0.45a	40.7	14.0	1.44	32.2	6.00	0.533	29.3	6.14	<llq<sup>d</llq<sup>	
0.45b	34.7	13.9	1.38	36.9	5.71	0.592	37.0	6.13	<llq <sup="">d</llq>	
0.45c	32.3	12.4	1.25	33.6	5.16	0.509	29.3	5.33	0.376	
Average:	35.9	13.4	1.36	34.2	5.62	0.545	31.9	5.87	0.370	
%RSD:	12.1%	6.67%	7.16%	7.05%	7.59%	7.84%	14.0%	7.92%	1.4%	
0.9a	111	22.4	1.56	No Peak	9.30	0.979	102	7.87	0.391	
				е						
0.9b	74.8	15.9	1.18	91.5	10.0	0.904	66.6	6.13	<llq <sup="">d</llq>	
0.9c	83.8	14.4	1.01	96.3	9.56	1.11	92.0	7.55	0.845	
Average:	89.9	17.6	1.25	93.9	9.62	1.00	86.9	7.18	0.534	
%RSD:	21.0%	24.2%	22.5%	NA (n=2)	3.68%	10.5%	21.0%	12.9%	50.4%	
1.8a	170	17.8	0.934	264	19.3	1.71	142	7.97	<llq<sup>d</llq<sup>	
1.8b	175	18.1	0.907	185	12.9	1.08	145	8.03	<llq<sup>d</llq<sup>	
1.8c	187	17.7	0.987	199	13.2	1.10	130	8.26	<llq<sup>d</llq<sup>	

Table S-1. Summary of Ethylbenzene, 1-Phenylethanol, and Acetophenone Quantitation of Liver Incubation Samples

Average:	177	17.9	0.943	216	15.1	1.30	139	8.09	<llq <sup="">d</llq>
%RSD:	4.93%	1.17%	4.32%	19.5%	23.9%	27.6%	5.71%	1.89%	
3.5a	f	19.1	1.01	286	17.5	1.19	313	8.69	0.490
3.5b	f	17.8	0.858	269	16.1	1.25	293	10.5	0.601
3.5c	f	17.8	0.904	268	14.3	1.09	246	8.28	<llq <sup="">d</llq>
Average:	NA	18.2	0.924	274	16.0	1.18	284	9.16	0.486
%RSD:	NA	4.12%	8.44%	3.69%	10.0%	6.87%	12.1%	12.9%	24.1%
7a	f	25.8	1.20	f	19.7	1.59	f	12.4	0.401
7b	f	19.4	0.916	f	17.6	1.57	f	11.8	0.473
7c	f	18.5	0.906	f	16.1	1.44	f	8.48	0.511
Average:	NA	21.2	1.01	NA	17.8	1.53	NA	10.9	0.462
%RSD:	NA	18.7%	16.57%	NA	10.2%	5.31%	NA	19.4%	12.1%

<sup>a</sup> Data collected in initial analysis for ethylbenzene where systemic ethylbenzene contamination was observed. <sup>b</sup> <LLQ = less than lowest level quantitated = 2.32 ug ethylbenzene/mL

<sup>c</sup> <LLQ = less than lowest level quantitated = 0.360 ug 1-phenylethanol/mL

<sup>d</sup> <LLQ = less than lowest level quantitated = 0.367 ug acetophenone/mL

<sup>e</sup> No peaks for either ethylbenzene or internal standard - suspect injection error.

<sup>f</sup> These samples being re-assayed to check EB concentrations

Mouse Liver Incubations						Rat Liver Incubations						Human Liver Incubations						
		2EP-GSH			4EP-GSH			2EP-GSH	1		4EP-GSH			2EP-GSH			4EP-GSH	
Treatment	(ng/mL)	mM	% Conversion	(ng/mL)	mМ	% Conversion	(ng/mL)	mМ	% Conversion	(ng/mL)	mМ	% Conversion	(ng/mL)	mМ	% Conversion	(ng/mL)	mM	% Conversion
Control no microsomes	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></llq<>	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Control no substrate	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td>4.20</td><td>9.482E-06</td><td>NA</td><td>2.8647484</td><td>6.467E-06</td><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td>4.20</td><td>9.482E-06</td><td>NA</td><td>2.8647484</td><td>6.467E-06</td><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td>4.20</td><td>9.482E-06</td><td>NA</td><td>2.8647484</td><td>6.467E-06</td><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>4.20</td><td>9.482E-06</td><td>NA</td><td>2.8647484</td><td>6.467E-06</td><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	4.20	9.482E-06	NA	2.8647484	6.467E-06	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA
0.45 no NADPH	5.81	1.31E-05	0.00291%	<llq< td=""><td><llq< td=""><td>NA</td><td>4.74</td><td>1.07E-05</td><td>0.00238%</td><td><llq< td=""><td><llq< td=""><td>NA</td><td>15.7</td><td>3.54E-05</td><td>0.00787%</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>4.74</td><td>1.07E-05</td><td>0.00238%</td><td><llq< td=""><td><llq< td=""><td>NA</td><td>15.7</td><td>3.54E-05</td><td>0.00787%</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	4.74	1.07E-05	0.00238%	<llq< td=""><td><llq< td=""><td>NA</td><td>15.7</td><td>3.54E-05</td><td>0.00787%</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>15.7</td><td>3.54E-05</td><td>0.00787%</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	15.7	3.54E-05	0.00787%	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA
1.8 no NADPH	20.9	4.71E-05	0.00262%	<llq< td=""><td><llq< td=""><td>NA</td><td>22.9</td><td>5.17E-05</td><td>0.00287%</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td></td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>22.9</td><td>5.17E-05</td><td>0.00287%</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td></td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	22.9	5.17E-05	0.00287%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td></td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td></td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td></td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td></td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>		<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA
7 no NADPH	61.9	1.40E-04	0.00199%	<llq< td=""><td><llq< td=""><td>NA</td><td>58.4</td><td>1.32E-04</td><td>0.00188%</td><td><llq< td=""><td><llq< td=""><td>NA</td><td>22.7</td><td>5.13E-05</td><td>0.000733%</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>58.4</td><td>1.32E-04</td><td>0.00188%</td><td><llq< td=""><td><llq< td=""><td>NA</td><td>22.7</td><td>5.13E-05</td><td>0.000733%</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	58.4	1.32E-04	0.00188%	<llq< td=""><td><llq< td=""><td>NA</td><td>22.7</td><td>5.13E-05</td><td>0.000733%</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>22.7</td><td>5.13E-05</td><td>0.000733%</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	22.7	5.13E-05	0.000733%	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA
0.22a	265	5.99E-04	0.272%	13.6	3.08E-05	0.0140%	32.0	7.23E-05	0.0329%	3.62	8.18E-06	0.00372%	22.5	5.09E-05	0.0231%	38.6	8.70E-05	0.0396%
0.22b	299	6.75E-04	0.307%	18.8	4.25E-05	0.0193%	24.7	5.58E-05	0.0254%	4.53	1.02E-05	0.00465%	22.1	5.00E-05	0.0227%	39.7	8.96E-05	0.0407%
0.22c	278	6.28E-04	0.286%	17.3	3.90E-05	0.0177%	23.0	5.18E-05	0.0236%	3.69	8.33E-06	0.00378%	25.4	5.73E-05	0.0261%	38.0	8.57E-05	0.0389%
Average:	281	6.34E-04	0.288%	16.6	3.74E-05	0.0170%	26.6	6.00E-05	0.0273%	3.95	8.91E-06	0.00405%	23.4	5.27E-05	0.0240%	38.7	8.74E-05	0.0397%
%RSD:	6.07%	6.07%	6.07%	16.0%	16.0%	16.0%	18.1%	18.1%	18.1%	12.8%	12.8%	12.8%	7.59%	7.59%	7.59%	2.27%	2.27%	2.27%
0.45a	251	5.66E-04	0.126%	14.7	3.31E-05	0.00737%	29.2	6.59E-05	0.0147%	<llq< td=""><td><llq< td=""><td>NA</td><td>36.0</td><td>8.13E-05</td><td>0.0181%</td><td>37.9</td><td>8.55E-05</td><td>0.0190%</td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>36.0</td><td>8.13E-05</td><td>0.0181%</td><td>37.9</td><td>8.55E-05</td><td>0.0190%</td></llq<>	NA	36.0	8.13E-05	0.0181%	37.9	8.55E-05	0.0190%
0.45b	238	5.37E-04	0.119%	14.1	3.19E-05	0.00709%	27.0	6.09E-05	0.0135%	<llq< td=""><td><llq< td=""><td>NA</td><td>24.7</td><td>5.56E-05</td><td>0.0124%</td><td>34.1</td><td>7.69E-05</td><td>0.0171%</td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>24.7</td><td>5.56E-05</td><td>0.0124%</td><td>34.1</td><td>7.69E-05</td><td>0.0171%</td></llq<>	NA	24.7	5.56E-05	0.0124%	34.1	7.69E-05	0.0171%
0.45c	252	5.69E-04	0.126%	12.6	2.85E-05	0.00633%	21.6	4.88E-05	0.0108%	1.68	3.79E-06	0.000843%	19.7	4.44E-05	0.0099%	26.1	5.88E-05	0.0131%
Average:	247	5.57E-04	0.124%	13.8	3.12E-05	0.00693%	25.9	5.85E-05	0.0130%	1.65	3.73E-06	0.000829%	26.8	6.04E-05	0.0134%	32.7	7.38E-05	0.0164%
%RSD:	3.20%	3.20%	3.20%	7.76%	7.76%	7.76%	15.1%	15.1%	15.1%	1.4%	1.4%	1.4%	31.3%	31.3%	31.3%	18.5%	18.5%	18.5%
0.9a	227	5.12E-04	0.0569%	12.6	2.85E-05	0.00317%	39.4	8.90E-05	0.00989%	2.00	4.51E-06	0.000501%	45.9	1.04E-04	0.0115%	24.7	5.58E-05	0.00620%
0.9b	201	4.55E-04	0.0505%	9.30	2.10E-05	0.00233%	36.1	8.15E-05	0.00905%	1.68	3.80E-06	0.000422%	29.8	6.72E-05	0.00747%	25.7	5.80E-05	0.00644%
0.9c	184	4.15E-04	0.0461%	7.92	1.79E-05	0.00199%	26.2	5.91E-05	0.00657%	<llq< td=""><td><llq< td=""><td>NA</td><td>31.0</td><td>7.00E-05</td><td>0.00777%</td><td>27.5</td><td>6.21E-05</td><td>0.00690%</td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>31.0</td><td>7.00E-05</td><td>0.00777%</td><td>27.5</td><td>6.21E-05</td><td>0.00690%</td></llq<>	NA	31.0	7.00E-05	0.00777%	27.5	6.21E-05	0.00690%
Average:	204	4.61E-04	0.0512%	9.95	2.25E-05	0.00250%	33.9	7.65E-05	0.00850%	1.77	4.00E-06	0.000445%	35.6	8.03E-05	0.00892%	26.0	5.86E-05	0.00651%
%RSD:	10.6%	10.6%	10.6%	24.4%	24.4%	24.4%	20.3%	20.3%	20.3%	11.1%	11.1%	11.1%	25.2%	25.2%	25.2%	5.48%	5.48%	5.48%
1.8a	166	3.74E-04	0.0208%	5.92	1.34E-05	0.000742%	42.3	9.56E-05	0.00531%	1.75	3.94E-06	0.000219%	66.4	1.50E-04	0.00833%	20.8	4.69E-05	0.00261%
1.8b	166	3.75E-04	0.0208%	5.38	1.21E-05	0.000674%	41.1	9.27E-05	0.00515%	<llq< td=""><td><llq< td=""><td>NA</td><td>61.3</td><td>1.38E-04</td><td>0.00769%</td><td>19.8</td><td>4.47E-05</td><td>0.00248%</td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>61.3</td><td>1.38E-04</td><td>0.00769%</td><td>19.8</td><td>4.47E-05</td><td>0.00248%</td></llq<>	NA	61.3	1.38E-04	0.00769%	19.8	4.47E-05	0.00248%
1.8c	156	3.53E-04	0.0196%	6.43	1.45E-05	0.000807%	43.2	9.76E-05	0.00542%	<llq< td=""><td><llq< td=""><td>NA</td><td>56.5</td><td>1.27E-04</td><td>0.00708%</td><td>16.0</td><td>3.60E-05</td><td>0.00200%</td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>56.5</td><td>1.27E-04</td><td>0.00708%</td><td>16.0</td><td>3.60E-05</td><td>0.00200%</td></llq<>	NA	56.5	1.27E-04	0.00708%	16.0	3.60E-05	0.00200%
Average:	163	3.67E-04	0.0204%	5.91	1.33E-05	0.000741%	42.2	9.53E-05	0.00529%	1.68	3.78E-06	0.000210%	61.4	1.39E-04	0.00770%	18.8	4.25E-05	0.00236%
%RSD:	3.34%	3.34%	3.34%	8.96%	8.96%	8.96%	2.60%	2.60%	2.60%	3.8%	3.8%	3.8%	8.14%	8.14%	8.14%	13.5%	13.5%	13.5%
3.5a	177	4.00E-04	0.0114%	4.29	9.69E-06	0.000277%	64.9	1.47E-04	0.00419%	<llq< td=""><td><llq< td=""><td>NA</td><td>126</td><td>2.86E-04</td><td>0.00816%</td><td>13.2</td><td>2.99E-05</td><td>0.000853%</td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>126</td><td>2.86E-04</td><td>0.00816%</td><td>13.2</td><td>2.99E-05</td><td>0.000853%</td></llq<>	NA	126	2.86E-04	0.00816%	13.2	2.99E-05	0.000853%
3.5b	148	3.33E-04	0.00952%	4.14	9.34E-06	0.000267%	63.5	1.43E-04	0.00409%	4.07	9.19E-06	0.000263%	119	2.68E-04	0.00765%	12.0	2.71E-05	0.000774%
3.5c	139	3.14E-04	0.00897%	5.81	1.31E-05	0.000375%	76.5	1.73E-04	0.00493%	<llq< td=""><td><llq< td=""><td>NA</td><td>72.0</td><td>1.63E-04</td><td>0.00465%</td><td>1.81</td><td>4.09E-06</td><td>0.000117%</td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>72.0</td><td>1.63E-04</td><td>0.00465%</td><td>1.81</td><td>4.09E-06</td><td>0.000117%</td></llq<>	NA	72.0	1.63E-04	0.00465%	1.81	4.09E-06	0.000117%
Average:	155	3.49E-04	0.00997%	4.75	1.07E-05	0.000306%	68.3	1.54E-04	0.00440%	2.45	5.53E-06	0.000158%	106	2.39E-04	0.00682%	9.01	2.03E-05	0.000581%
%RSD:	12.9%	12.9%	12.9%	19.5%	19.5%	19.5%	10.5%	10.5%	10.5%	57.3%	57.3%	57.3%	27.8%	27.8%	27.8%	69.5%	69.5%	69.5%
/a	223	5.03E-04	0.00719%	3.34	7.54E-06	0.000108%	117	2.63E-04	0.00376%	4.41	9.95E-06	0.000142%	136	3.06E-04	0.00437%	14.3	3.22E-05	0.000460%
7b	167	3.77E-04	0.00539%	3.51	7.93E-06	0.000113%	127	2.86E-04	0.00409%	5.07	1.14E-05	0.000163%	116	2.62E-04	0.00375%	12.2	2.74E-05	0.000392%
/C	185	4.18E-04	0.00598%	2.91	0.58E-06	0.0000939%	128	2.90E-04	0.00414%	5.13	1.16E-05	0.000166%	106	2.39E-04	0.00342%	8.9	2.00E-05	0.000286%
Average:	1/ 8%	4.33E-04 1/ 8%	1/ 8%	3.20 0.51%	1.35E-06 0.51%	0.000105%	124 5 1/9/	2.80E-04	5 1 4%	4.8/ 8.22%	1.10E-05	0.000157% 8.22%	119	12.6%	0.00385%	11.8 23.2%	2.00E-05	0.000379%
%RSD.	14.0%	14.0%	14.0%	9.01%	9.01%	9.01%	0.14%	0.14%	5.14%	0.22%	0.22%	0.22%	12.0%	12.0%	12.0%	23.2%	23.2%	23.2%

# Table S-2. Summary of 2-Ethylphenol-GSH and 4-Ethylphenol-GSH Data from Liver Incubation Samples

<LLQ = less than lowest level quantitated = 2.32 ng 2EP-GSH/mL (5 x  $10^{-6}$  mM) and 1.64 ng 4EP-GSH/mL (4 x  $10^{-6}$  mM)

	Mouse	e Lung Incu	ubations	Rat Lu	ung Incub	ations	Human	Human Lung Incubations			
Treatment	EB	1-PE	AcPh	EB	1-PE	AcPh	EB	1-PE	AcPh		
	(ug/mL)	(ug/mL)	(ug/mL)	(ug/mL)	(ug/mL)	(ug/mL)	(ug/mL)	(ug/mL)	(ug/mL)		
Control no	34.9	<llq <sup="">▷</llq>	<llq <sup="">c</llq>								
microsomes									0.450		
Control no	<llq "<="" td=""><td><llq td="" °<=""><td><llq td="" °<=""><td><llq "<="" td=""><td><llq td="" °<=""><td><llq td="" °<=""><td><llq "<="" td=""><td><llq td="" °<=""><td>0.452</td></llq></td></llq></td></llq></td></llq></td></llq></td></llq></td></llq></td></llq>	<llq td="" °<=""><td><llq td="" °<=""><td><llq "<="" td=""><td><llq td="" °<=""><td><llq td="" °<=""><td><llq "<="" td=""><td><llq td="" °<=""><td>0.452</td></llq></td></llq></td></llq></td></llq></td></llq></td></llq></td></llq>	<llq td="" °<=""><td><llq "<="" td=""><td><llq td="" °<=""><td><llq td="" °<=""><td><llq "<="" td=""><td><llq td="" °<=""><td>0.452</td></llq></td></llq></td></llq></td></llq></td></llq></td></llq>	<llq "<="" td=""><td><llq td="" °<=""><td><llq td="" °<=""><td><llq "<="" td=""><td><llq td="" °<=""><td>0.452</td></llq></td></llq></td></llq></td></llq></td></llq>	<llq td="" °<=""><td><llq td="" °<=""><td><llq "<="" td=""><td><llq td="" °<=""><td>0.452</td></llq></td></llq></td></llq></td></llq>	<llq td="" °<=""><td><llq "<="" td=""><td><llq td="" °<=""><td>0.452</td></llq></td></llq></td></llq>	<llq "<="" td=""><td><llq td="" °<=""><td>0.452</td></llq></td></llq>	<llq td="" °<=""><td>0.452</td></llq>	0.452		
substrate											
0.45 po	3/1 1			36.4			27.2				
NADPH	54.1			50.4			21.2				
1.8 no NADPH	127	<llq <sup="">b</llq>	<llq td="" °<=""><td>141</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""><td>112</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""></llq></td></llq></td></llq>	141	<llq <sup="">b</llq>	<llq td="" °<=""><td>112</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""></llq></td></llq>	112	<llq <sup="">b</llq>	<llq td="" °<=""></llq>		
7 no NADPH	473	<llq <sup="">b</llq>	<llq td="" °<=""><td>585</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""><td>542</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""></llq></td></llq></td></llq>	585	<llq <sup="">b</llq>	<llq td="" °<=""><td>542</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""></llq></td></llq>	542	<llq <sup="">b</llq>	<llq td="" °<=""></llq>		
0.22a	8.84	15.3	1.86	16.0	8.27	0.371	20.9	<llq <sup="">▷</llq>	<llq <sup="">c</llq>		
0.22b	7.79	15.2	1.79	15.1	8.11	<llq <sup="">c</llq>	19.5	<llq <sup="">b</llq>	<llq td="" °<=""></llq>		
0.22c	6.97	15.9	1.90	14.2	8.02	0.369	22.1	<llq <sup="">b</llq>	<llq td="" °<=""></llq>		
Average:	7.87	15.5	1.85	15.1	8.13	0.369	20.8	<llq <sup="">b</llq>	<llq <sup="">c</llq>		
%RSD:	11.9%	2.45%	3.01%	5.96%	1.56%	0.54%	6.25%				
								h			
0.45a	15.4	24.8	2.42	25.2	9.11	<llq td="" °<=""><td>38.7</td><td><llq <sup="">®</llq></td><td>° sLLQ</td></llq>	38.7	<llq <sup="">®</llq>	° sLLQ		
0.45b	14.8	30.3	2.77	25.1	9.04	<llq <sup="">c</llq>	42.3	<llq <sup="">D</llq>	<llq td="" °<=""></llq>		
0.45c	15.3	30.2	2.65	24.3	9.24	<llq <sup="">c</llq>	40.6	<llq <sup="">b</llq>	<llq td="" °<=""></llq>		
Average:	15.2	28.4	2.61	24.9	9.13	<llq <math="">^{\circ}</llq>	40.5	<llq <sup="">b</llq>	<llq td="" °<=""></llq>		
%RSD:	2.12%	11.07%	6.81%	1.98%	1.11%		4.44%				
									-		
0.9a	43.8	45.6	2.85	51.0	9.74	<llq <sup="">c</llq>	100	<llq <sup="">®</llq>	<llq td="" °<=""></llq>		
0.9b	43.0	47.9	2.86	58.7	10.1	<llq <sup="">c</llq>	100	<llq <sup="">b</llq>	<llq td="" °<=""></llq>		
0.9c	45.2	47.6	2.43	55.8	9.52	<llq <sup="">c</llq>	106	<llq <sup="">b</llq>	<llq td="" °<=""></llq>		
Average:	44.0	47.0	2.71	55.2	9.79	<llq<sup>c</llq<sup>	102	<llq <sup="">b</llq>	<llq <sup="">c</llq>		
%RSD:	2.53%	2.66%	9.05%	7.05%	2.99%		3.40%				

 Table S-3. Summary of Ethylbenzene, 1-Phenylethanol, and Acetophenone Quantitation of Lung Incubation Samples

1.8a	131	53.6	2.51	112	10.0	<llq td="" °<=""><td>202</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""></llq></td></llq>	202	<llq <sup="">b</llq>	<llq td="" °<=""></llq>
1.8b	127	52.6	2.51	114	11.4	<llq td="" °<=""><td>205</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""></llq></td></llq>	205	<llq <sup="">b</llq>	<llq td="" °<=""></llq>
1.8c	126	50.6	2.16	125	10.0	<llq td="" °<=""><td>210</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""></llq></td></llq>	210	<llq <sup="">b</llq>	<llq td="" °<=""></llq>
Averaç	ge: <b>128</b>	52.3	2.39	117	10.5	<llq td="" °<=""><td>206</td><td><llq <sup="">b</llq></td><td><llq <sup="">c</llq></td></llq>	206	<llq <sup="">b</llq>	<llq <sup="">c</llq>
%RS	D: 2.07%	2.92%	8.44%	5.98%	7.72%		1.97%		
3.5a	281	52.8	2.61	233	10.6	<llq td="" °<=""><td>273</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""></llq></td></llq>	273	<llq <sup="">b</llq>	<llq td="" °<=""></llq>
3.5b	281	52.8	2.56	247	11.0	<llq td="" °<=""><td>316</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""></llq></td></llq>	316	<llq <sup="">b</llq>	<llq td="" °<=""></llq>
3.5c	292	49.1	2.20	255	10.7	<llq td="" °<=""><td>295</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""></llq></td></llq>	295	<llq <sup="">b</llq>	<llq td="" °<=""></llq>
Avera	ge: <b>285</b>	51.6	2.46	245	10.8	<llq <sup="">c</llq>	295	<llq <sup="">b</llq>	<llq <sup="">c</llq>
%RS	D: 2.23%	4.14%	9.11%	4.55%	1.93%		7.30%		
7a	d	58.6	2.81	d	10.2	<llq td="" °<=""><td>d</td><td><llq <sup="">▷</llq></td><td><llq td="" °<=""></llq></td></llq>	d	<llq <sup="">▷</llq>	<llq td="" °<=""></llq>
7b	d	51.8	2.16	d	11.2	<llq td="" °<=""><td>d</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""></llq></td></llq>	d	<llq <sup="">b</llq>	<llq td="" °<=""></llq>
7c	d	51.1	2.30	d	10.3	<llq td="" °<=""><td>d</td><td><llq <sup="">b</llq></td><td><llq td="" °<=""></llq></td></llq>	d	<llq <sup="">b</llq>	<llq td="" °<=""></llq>
Averaç	ge: NA	53.8	2.42	NA	10.6	<llq <sup="">c</llq>	NA	<llq <sup="">b</llq>	<llq <sup="">c</llq>
%RS	D: NA	7.70%	14.1%	NA	5.21%		NA		

 $^{\rm a}~$  <LLQ = less than lowest level quantitated = 2.32 ug ethylbenzene/mL

<sup>b</sup> <LLQ = less than lowest level quantitated = 0.360 ug 1-phenylethanol/mL

 $^{\circ}$  <LLQ = less than lowest level quantitated = 0.367 ug acetophenone/mL

<sup>d</sup> These samples being re-assayed to check EB concentrations

Mouse Lung Incubations						Rat Lung Incubations							Human Lung Incubations						
		2EP-GSH			4EP-GSH			2EP-GSH	1		4EP-GSH	1		2EP-GSH			4EP-GSH		
Treatment	(ng/mL)	mM	% Conversion	(ng/mL)	mM	% Conversion	(ng/mL)	mM	% Conversion	(ng/mL)	mM	% Conversion	(ng/mL)	mМ	% Conversion	(ng/mL)	mМ	% Conversion	
Control no microsomes	NA	NA	NA	NA	NA	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></llq<>	NA	NA	NA	NA	NA	NA	NA	
Control no substrate	3.64	8.21E-06	NA	<llq< td=""><td><llq< td=""><td>NA</td><td>2.55</td><td>5.752E-06</td><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td>2.55</td><td>5.752E-06</td><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	2.55	5.752E-06	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
0.45 no NADPH	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
1.8 no NADPH	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
7 no NADPH	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
0.22a	536	1.21E-03	0.550%	17.3	3.91E-05	0.0178%	52.3	1.18E-04	0.0537%	10.7	2.41E-05	0.0110%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
0.22b	542	1.22E-03	0.556%	16.0	3.61E-05	0.0164%	60.0	1.35E-04	0.0616%	12.6	2.84E-05	0.0129%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
0.22c	533	1.20E-03	0.547%	18.9	4.27E-05	0.0194%	59.3	1.34E-04	0.0609%	11.9	2.69E-05	0.0122%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
Average:	537	1.21E-03	0.551%	17.4	3.93E-05	0.0179%	57.2	1.29E-04	0.0587%	11.7	2.65E-05	0.0120%	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""></llq<></td></llq<>	<llq< td=""></llq<>	
%RSD:	0.84%	0.84%	0.84%	8.43%	8.43%	8.43%	7.42%	7.42%	7.42%	8.13%	8.13%	8.13%	NA	NA	NA	NA	NA	NA	
0.45a	510	1.15E-03	0.256%	24.9	5.62E-05	0.0125%	47.0	1.06E-04	0.0236%	8.80	1.99E-05	0.00441%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
0.45b	443	1.00E-03	0.222%	27.5	6.20E-05	0.0138%	45.4	1.02E-04	0.0228%	8.54	1.93E-05	0.00428%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
0.45c	467	1.05E-03	0.234%	24.5	5.54E-05	0.0123%	42.0	9.47E-05	0.0210%	8.63	1.95E-05	0.00433%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
Average:	473	1.07E-03	0.237%	25.6	5.79E-05	0.0129%	44.8	1.01E-04	0.0225%	8.65	1.95E-05	0.00434%	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""></llq<></td></llq<>	<llq< td=""></llq<>	
%RSD:	7.18%	7.18%	7.18%	6.23%	6.23%	6.23%	5.71%	5.71%	5.71%	1.51%	1.51%	1.51%	NA	NA	NA	NA	NA	NA	
0.9a	232	5.25E-04	0.0583%	18.5	4.17E-05	0.00463%	32.7	7.37E-05	0.00819%	6.45	1.46E-05	0.00162%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
0.9b	235	5.31E-04	0.0590%	19.8	4.47E-05	0.00496%	33.5	7.57E-05	0.00841%	6.25	1.41E-05	0.00157%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
0.9c	190	4.28E-04	0.0475%	17.2	3.88E-05	0.00431%	35.5	8.00E-05	0.00889%	6.89	1.56E-05	0.00173%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
Average:	219	4.94E-04	0.0549%	18.5	4.17E-05	0.00463%	33.9	7.65E-05	0.00850%	6.53	1.47E-05	0.00164%	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""></llq<></td></llq<>	<llq< td=""></llq<>	
%RSD:	11.7%	11.7%	11.7%	7.08%	7.08%	7.08%	4.22%	4.22%	4.22%	5.07%	5.07%	5.07%	NA	NA	NA	NA	NA	NA	
1.8a	124	2.80E-04	0.0156%	11.0	2.49E-05	0.00138%	25.5	5.75E-05	0.00320%	4.76	1.07E-05	0.000596%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
1.8b	142	3.20E-04	0.0178%	12.5	2.82E-05	0.00156%	26.2	5.90E-05	0.00328%	5.00	1.13E-05	0.000626%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
1.8c	123	2.78E-04	0.0155%	9.72	2.19E-05	0.00122%	25.7	5.79E-05	0.00322%	5.36	1.21E-05	0.000672%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
Average:	130	2.93E-04	0.0163%	11.1	2.50E-05	0.00139%	25.8	5.82E-05	0.00323%	5.04	1.14E-05	0.000632%	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""></llq<></td></llq<>	<llq< td=""></llq<>	
%RSD:	8.13%	8.13%	8.13%	12.5%	12.5%	12.5%	1.33%	1.33%	1.33%	6.03%	6.03%	6.03%	NA	NA	NA	NA	NA	NA	
3.5a	115	2.59E-04	0.00740%	9.87	2.23E-05	0.000637%	24.9	5.62E-05	0.00160%	4.53	1.02E-05	0.000292%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
3.5b	113	2.55E-04	0.00729%	9.61	2.17E-05	0.000620%	21.0	4.73E-05	0.00135%	3.87	8.73E-06	0.000250%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
3.5c	95.6	2.16E-04	0.00617%	8.09	1.83E-05	0.000522%	21.8	4.92E-05	0.00140%	3.50	7.90E-06	0.000226%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
Average:	108	2.43E-04	0.00695%	9.19	2.07E-05	0.000593%	22.5	5.09E-05	0.00145%	3.97	8.95E-06	0.000256%	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""><td><llq< td=""></llq<></td></llq<></td></llq<>	<llq< td=""><td><llq< td=""></llq<></td></llq<>	<llq< td=""></llq<>	
%RSD:	9.83%	9.83%	9.83%	10.5%	10.5%	10.5%	9.18%	9.18%	9.18%	13.2%	13.2%	13.2%	NA	NA	NA	NA	NA	NA	
7a	87.3	1.97E-04	0.00281%	6.13	1.38E-05	0.000198%	18.2	4.11E-05	0.000588%	2.71	6.12E-06	0.0000874%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
7b	66.6	1.50E-04	0.00215%	4.81	1.09E-05	0.000155%	17.6	3.98E-05	0.000569%	2.95	6.66E-06	0.0000951%	<llq< td=""><td><llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<></td></llq<>	<llq< td=""><td>NA</td><td><llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<></td></llq<>	NA	<llq< td=""><td><llq< td=""><td>NA</td></llq<></td></llq<>	<llq< td=""><td>NA</td></llq<>	NA	
7c	95.5	2.16E-04	0.00308%	7.67	1.73E-05	0.000247%	18.5	4.19E-05	0.000598%	3.18	7.18E-06	0.000103%	<llq< td=""><td></td><td>NA ILO</td><td></td><td></td><td>NA 110</td></llq<>		NA ILO			NA 110	
Average:	83.1	1.88E-04	0.00268%	6.20	1.40E-05	0.000200%	18.1	4.09E-05	0.000585%	2.95	6.65E-06	0.0000950%							
%RSD:	18.0%	18.0%	18.0%	23.1%	23.1%	23.1%	2.55%	2.55%	2.55%	7.92%	7.92%	7.92%	INA	INA	INA	INA	INA	INA	

# Table S-4. Summary of 2-Ethylphenol-GSH and 4-Ethylphenol-GSH Data from Lung Incubation Samples

<LLQ = less than lowest level quantitated = 2.32 ng 2EP-GSH/mL (5 x 10<sup>-6</sup> mM) and 1.64 ng 4EP-GSH/mL (4 x 10<sup>-6</sup> mM)



**Figure S-1**. Structures of 2,5-ethylquinone (abbrev. as 2EP-GSH in tables) and 3,4-ethylquinone (abbrev. as 4EP-GSH in tables) analyzed by HPLC/MRM/MS